{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:34:49Z","timestamp":1788564889489,"version":"build-2803163510"},"reference-count":293,"publisher":"China Science Publishing & Media Ltd.","issue":"1","content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2026,1,1]]},"DOI":"10.3724\/abbs.2025190","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T06:50:04Z","timestamp":1759992604000},"page":"3-24","update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":4,"title":["Decoding signaling architectures: CAR versus TCR dynamics in solid tumor immunotherapy"],"prefix":"10.3724","volume":"58","author":[{"given":"Zui","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2026","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"CITATION1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev-immunol-051116-052302","volume":"35","author":"Roybal KT","year":"2017","unstructured":"Roybal KT, Lim WA. Synthetic immunology: hacking immune cells to expand their therapeutic capabilities. Annu Rev Immunol, 2017, 35: 229-253.","journal-title":"Annu Rev Immunol"},{"key":"CITATION2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"Rafiq S","year":"2019","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol, 2019, 17: 147-167.","journal-title":"Nat Rev Clin Oncol"},{"key":"CITATION3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nchembio.2565","volume":"14","author":"Chang ZNL","year":"2018","unstructured":"Chang ZNL, Lorenzini MH, Chen X, Tran U, Bangayan NJ, Chen YY. Rewiring T-cell responses to soluble factors with chimeric antigen receptors. Nat Chem Biol, 2018, 14: 317-324.","journal-title":"Nat Chem Biol"},{"key":"CITATION4","doi-asserted-by":"publisher","first-page":"e002173","DOI":"10.1136\/jitc-2020-002173","volume":"9","author":"Wang G","year":"2021","unstructured":"Wang G, Zhou X, Fuc\u00e0 G, Dukhovlinova E, Shou P, Li H, Johnston C. Fully human antibody VH domains to generate mono and bispecific CAR to target solid tumors. J Immunother Cancer, 2021, 9: e002173.","journal-title":"J Immunother Cancer"},{"key":"CITATION5","doi-asserted-by":"publisher","first-page":"5951","DOI":"10.1158\/1078-0432.CCR-20-2754","volume":"27","author":"Ranganathan R","year":"2021","unstructured":"Ranganathan R, Shou P, Ahn S, Sun C, West J, Savoldo B, Dotti G. CAR T cells targeting human immunoglobulin light chains eradicate mature B-cell malignancies while sparing a subset of normal B cells. Clin Cancer Res, 2021, 27: 5951-5960.","journal-title":"Clin Cancer Res"},{"key":"CITATION6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","volume":"353","author":"Ellebrecht CT","year":"2016","unstructured":"Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, Di Zenzo G. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science, 2016, 353: 179-184.","journal-title":"Science"},{"key":"CITATION7","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1182\/bloodadvances.2019000703","volume":"3","author":"Schmidts A","year":"2019","unstructured":"Schmidts A, Ormh\u00f8j M, Choi BD, Taylor AO, Bouffard AA, Scarf\u00f2 I, Larson RC. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Adv, 2019, 3: 3248-3260.","journal-title":"Blood Adv"},{"key":"CITATION8","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"Brown CE","year":"2016","unstructured":"Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med, 2016, 375: 2561-2569.","journal-title":"N Engl J Med"},{"key":"CITATION9","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1038\/s41591-025-03745-0","volume":"31","author":"Bagley SJ","year":"2025","unstructured":"Bagley SJ, Desai AS, Fraietta JA, Silverbush D, Chafamo D, Freeburg NF, Gopikrishna GK. Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R\u03b12 in recurrent glioblastoma: a phase 1 trial. Nat Med, 2025, 31: 2778-2787.","journal-title":"Nat Med"},{"key":"CITATION10","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","volume":"25","author":"Ying Z","year":"2019","unstructured":"Ying Z, Huang XF, Xiang X, Liu Y, Kang X, Song Y, Guo X. A safe and potent anti-CD19 CAR T cell therapy. Nat Med, 2019, 25: 947-953.","journal-title":"Nat Med"},{"key":"CITATION11","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41577-025-01146-5","volume":"25","author":"Flemming A","year":"2025","unstructured":"Flemming A. Trogocytosis of CARs depends on transmembrane domains. Nat Rev Immunol, 2025, 25: 156.","journal-title":"Nat Rev Immunol"},{"key":"CITATION12","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"Sadelain M","year":"2013","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I. The basic principles of chimeric antigen receptor design. Cancer Discov, 2013, 3: 388-398.","journal-title":"Cancer Discov"},{"key":"CITATION13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","volume":"12","author":"Guedan S","year":"2019","unstructured":"Guedan S, Calderon H, Posey Jr. AD, Maus MV. Engineering and design of chimeric antigen receptors. Mol Ther-Methods Clin Dev, 2019, 12: 145-156.","journal-title":"Mol Ther-Methods Clin Dev"},{"key":"CITATION14","doi-asserted-by":"publisher","first-page":"eaat6753","DOI":"10.1126\/scisignal.aat6753","volume":"11","author":"Salter AI","year":"2018","unstructured":"Salter AI, Ivey RG, Kennedy JJ, Voillet V, Rajan A, Alderman EJ, Voytovich UJ. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci Signal, 2018, 11: eaat6753.","journal-title":"Sci Signal"},{"key":"CITATION15","doi-asserted-by":"publisher","first-page":"eaap9777","DOI":"10.1126\/scisignal.aap9777","volume":"12","author":"Ramello MC","year":"2019","unstructured":"Ramello MC, Benza\u00efd I, Kuenzi BM, Lienlaf-Moreno M, Kandell WM, Santiago DN, Pab\u00f3n-Salda\u00f1a M. An immunoproteomic approach to characterize the CAR interactome and signalosome. Sci Signal, 2019, 12: eaap9777.","journal-title":"Sci Signal"},{"key":"CITATION16","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ccell.2019.12.014","volume":"37","author":"Sun C","year":"2020","unstructured":"Sun C, Shou P, Du H, Hirabayashi K, Chen Y, Herring LE, Ahn S. THEMIS-SHP1 recruitment by 4-1BB tunes LCK-mediated priming of chimeric antigen receptor-redirected T cells. Cancer Cell, 2020, 37: 216-225.e6.","journal-title":"Cancer Cell"},{"key":"CITATION17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3389\/fmed.2018.00343","volume":"5","author":"Omer B","year":"2018","unstructured":"Omer B, Castillo PA, Tashiro H, Shum T, Huynh MTA, Cardenas M, Tanaka M. Chimeric antigen receptor signaling domains differentially regulate proliferation and native T cell receptor function in virus-specific T cells. Front Med, 2018, 5: 343.","journal-title":"Front Med"},{"key":"CITATION18","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41422-023-00789-0","volume":"33","author":"Chen J","year":"2023","unstructured":"Chen J, Qiu S, Li W, Wang K, Zhang Y, Yang H, Liu B. Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness. Cell Res, 2023, 33: 341-354.","journal-title":"Cell Res"},{"key":"CITATION19","doi-asserted-by":"publisher","DOI":"10.3724\/abbs.2024034","author":"Zhao X","year":"2024","unstructured":"Zhao X, Shao S, Hu L. The recent advancement of TCR-T cell therapies for cancer treatment. Acta Biochim Biophys Sin, 2024.","journal-title":"Acta Biochim Biophys Sin"},{"key":"CITATION20","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/imr.12000","volume":"250","author":"Kuhns MS","year":"2012","unstructured":"Kuhns MS, Badgandi HB. Piecing together the family portrait of TCR-CD3 complexes. Immunol Rev, 2012, 250: 120-143.","journal-title":"Immunol Rev"},{"key":"CITATION21","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","volume":"6","author":"Shah K","year":"2021","unstructured":"Shah K, Al-Haidari A, Sun J, Kazi JU. T cell receptor (TCR) signaling in health and disease. Sig Transduct Target Ther, 2021, 6: 412.","journal-title":"Sig Transduct Target Ther"},{"key":"CITATION22","doi-asserted-by":"publisher","first-page":"21336","DOI":"10.1073\/pnas.2005899117","volume":"117","author":"Hwang W","year":"2020","unstructured":"Hwang W, Mallis RJ, Lang MJ, Reinherz EL. The \u03b1\u03b2 TCR mechanosensor exploits dynamic ectodomain allostery to optimize its ligand recognition site. Proc Natl Acad Sci USA, 2020, 117: 21336-21345.","journal-title":"Proc Natl Acad Sci USA"},{"key":"CITATION23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.cell.2014.02.053","volume":"157","author":"Liu B","year":"2014","unstructured":"Liu B, Chen W, Evavold BD, Zhu C. Accumulation of dynamic catch bonds between TCR and agonist peptide-MHC triggers T cell signaling. Cell, 2014, 157: 357-368.","journal-title":"Cell"},{"key":"CITATION24","doi-asserted-by":"publisher","first-page":"011304","DOI":"10.1063\/5.0166848","volume":"11","author":"Jeffreys N","year":"2024","unstructured":"Jeffreys N, Brockman JM, Zhai Y, Ingber DE, Mooney DJ. Mechanical forces amplify TCR mechanotransduction in T cell activation and function. Appl Phys Rev, 2024, 11: 011304.","journal-title":"Appl Phys Rev"},{"key":"CITATION25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3389\/fimmu.2012.00076","volume":"3","author":"Kim ST","year":"2012","unstructured":"Kim ST, Shin Y, Brazin K, Mallis RJ, Sun ZYJ, Wagner G, Lang MJ. TCR mechanobiology: torques and tunable structures linked to early T cell signaling. Front Immun, 2012, 3: 76.","journal-title":"Front Immun"},{"key":"CITATION26","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41590-020-0732-3","volume":"21","author":"Hartl FA","year":"2020","unstructured":"Hartl FA, Beck-Garc\u00eca E, Woessner NM, Flachsmann LJ, C\u00e1rdenas RMHV, Brandl SM, Taromi S. Noncanonical binding of Lck to CD3\u03b5 promotes TCR signaling and CAR function. Nat Immunol, 2020, 21: 902-913.","journal-title":"Nat Immunol"},{"key":"CITATION27","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41586-019-1537-0","volume":"573","author":"Dong D","year":"2019","unstructured":"Dong D, Zheng L, Lin J, Zhang B, Zhu Y, Li N, Xie S. Structural basis of assembly of the human T cell receptor\u2013CD3 complex. Nature, 2019, 573: 546-552.","journal-title":"Nature"},{"key":"CITATION28","doi-asserted-by":"publisher","first-page":"e67195","DOI":"10.7554\/eLife.67195","volume":"10","author":"Pandey PR","year":"2021","unstructured":"Pandey PR, R\u00f3\u017cycki B, Lipowsky R, Weikl TR. Structural variability and concerted motions of the T cell receptor \u2013 CD3 complex. eLife, 2021, 10: e67195.","journal-title":"eLife"},{"key":"CITATION29","doi-asserted-by":"publisher","first-page":"e2217301120","DOI":"10.1073\/pnas.2217301120","volume":"120","author":"Chen H","year":"2023","unstructured":"Chen H, Xu X, Hu W, Wu S, Xiao J, Wu P, Wang X. Self-programmed dynamics of T cell receptor condensation. Proc Natl Acad Sci USA, 2023, 120: e2217301120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"CITATION30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1146\/annurev-immunol-042617-053335","volume":"36","author":"Au-Yeung BB","year":"2018","unstructured":"Au-Yeung BB, Shah NH, Shen L, Weiss A. ZAP-70 in signaling, biology, and disease. Annu Rev Immunol, 2018, 36: 127-156.","journal-title":"Annu Rev Immunol"},{"key":"CITATION31","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1038\/s41590-022-01288-x","volume":"23","author":"Voisinne G","year":"2022","unstructured":"Voisinne G, Locard-Paulet M, Froment C, Maturin E, Menoita MG, Girard L, Mellado V. Kinetic proofreading through the multi-step activation of the ZAP70 kinase underlies early T cell ligand discrimination. Nat Immunol, 2022, 23: 1355-1364.","journal-title":"Nat Immunol"},{"key":"CITATION32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00018-022-04657-9","volume":"80","author":"Anto NP","year":"2023","unstructured":"Anto NP, Arya AK, Muraleedharan A, Shaik J, Nath PR, Livneh E, Sun Z. Cyclophilin A associates with and regulates the activity of ZAP70 in TCR\/CD3-stimulated T cells. Cell Mol Life Sci, 2023, 80: 7.","journal-title":"Cell Mol Life Sci"},{"key":"CITATION33","doi-asserted-by":"publisher","first-page":"e202009154","DOI":"10.1083\/jcb.202009154","volume":"220","author":"Zeng L","year":"2021","unstructured":"Zeng L, Palaia I, \u0160ari\u0107 A, Su X. PLC\u03b31 promotes phase separation of T cell signaling components. J Cell Biol, 2021, 220: e202009154.","journal-title":"J Cell Biol"},{"key":"CITATION34","doi-asserted-by":"publisher","first-page":"8674","DOI":"10.1021\/bi992558t","volume":"39","author":"Kim MJ","year":"2000","unstructured":"Kim MJ, Chang JS, Park SK, Hwang JI, Ryu SH, Suh PG. Direct interaction of SOS1 ras exchange protein with the SH3 domain of phospholipase C-\u03b31. Biochemistry, 2000, 39: 8674-8682.","journal-title":"Biochemistry"},{"key":"CITATION35","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nsmb1133","volume":"13","author":"Houtman JCD","year":"2006","unstructured":"Houtman JCD, Yamaguchi H, Barda-Saad M, Braiman A, Bowden B, Appella E, Schuck P. Oligomerization of signaling complexes by the multipoint binding of GRB2 to both LAT and SOS1. Nat Struct Mol Biol, 2006, 13: 798-805.","journal-title":"Nat Struct Mol Biol"},{"key":"CITATION36","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1084\/jem.194.2.135","volume":"194","author":"Sommers CL","year":"2001","unstructured":"Sommers CL, Menon RK, Grinberg A, Zhang W, Samelson LE, Love PE. Knock-in mutation of the distal four tyrosines of linker for activation of T cells blocks murine T cell development. J Exp Med, 2001, 194: 135-142.","journal-title":"J Exp Med"},{"key":"CITATION37","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.aad9964","volume":"352","author":"Su X","year":"2016","unstructured":"Su X, Ditlev JA, Hui E, Xing W, Banjade S, Okrut J, King DS. Phase separation of signaling molecules promotes T cell receptor signal transduction. Science, 2016, 352: 595-599.","journal-title":"Science"},{"key":"CITATION38","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","volume":"615","author":"Tousley AM","year":"2023","unstructured":"Tousley AM, Rotiroti MC, Labanieh L, Rysavy LW, Kim WJ, Lareau C, Sotillo E. Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature, 2023, 615: 507-516.","journal-title":"Nature"},{"key":"CITATION39","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1016\/j.bpj.2020.04.018","volume":"118","author":"Lin JJ","year":"2020","unstructured":"Lin JJ, O\u2032Donoghue GP, Wilhelm KB, Coyle MP, Low-Nam ST, Fay NC, Alfieri KN. Membrane association transforms an inert anti-TCR\u03b2 Fab\u2032 ligand into a potent T cell receptor agonist. Biophys J, 2020, 118: 2879-2893.","journal-title":"Biophys J"},{"key":"CITATION40","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.immuni.2025.07.018","volume":"58","author":"Lv J","year":"2025","unstructured":"Lv J, Si T, Wang D, Zhang C, Zhou Y, Yu J, Jiang Y. Mechanical signaling via \u03b22 integrin decouples T cell proliferation and differentiation for generating stem cell-like CAR T cells. Immunity, 2025, 58: 2289-2304.e10.","journal-title":"Immunity"},{"key":"CITATION41","doi-asserted-by":"publisher","first-page":"120058","DOI":"10.1016\/j.biomaterials.2020.120058","volume":"252","author":"Majedi FS","year":"2020","unstructured":"Majedi FS, Hasani-Sadrabadi MM, Thauland TJ, Li S, Bouchard LS, Butte MJ. T-cell activation is modulated by the 3D mechanical microenvironment. Biomaterials, 2020, 252: 120058.","journal-title":"Biomaterials"},{"key":"CITATION42","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s42003-021-02995-1","volume":"5","author":"Al-Aghbar MA","year":"2022","unstructured":"Al-Aghbar MA, Jainarayanan AK, Dustin ML, Roffler SR. The interplay between membrane topology and mechanical forces in regulating T cell receptor activity. Commun Biol, 2022, 5: 40.","journal-title":"Commun Biol"},{"key":"CITATION43","doi-asserted-by":"crossref","unstructured":"Hu Y, Duan Y, Velusamy A, Narum S, Rogers J, Salaita K. DNA Origami Tension Sensors (DOTS) to study T cell receptor mechanics at membrane junctions.  bioRxiv  2023.","DOI":"10.1101\/2023.07.09.548279"},{"key":"CITATION44","doi-asserted-by":"publisher","first-page":"11558","DOI":"10.1200\/JCO.2023.41.16_suppl.11558","volume":"41","author":"Kawai A","year":"2023","unstructured":"Kawai A, Ishihara M, Nakamura T, Kitano S, Iwata S, Takada K, Emori M. Results from phase I\/II study of NY-ESO-1-specific TCR gene-transduced T cell therapy (TBI-1301, mipetresgene autoleucel) in patients with advanced synovial sarcoma. J Clin Oncol, 2023, 41: 11558.","journal-title":"J Clin Oncol"},{"key":"CITATION45","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/1078-0432.CCR-13-3017","volume":"20","author":"Chodon T","year":"2014","unstructured":"Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res, 2014, 20: 2457-2465.","journal-title":"Clin Cancer Res"},{"key":"CITATION46","doi-asserted-by":"publisher","first-page":"217432","DOI":"10.1016\/j.canlet.2024.217432","volume":"611","author":"Kong S","year":"2025","unstructured":"Kong S, Zhang J, Wang L, Li W, Guo H, Weng Q, He Q. Mechanisms of low MHC I expression and strategies for targeting MHC I with small molecules in cancer immunotherapy. Cancer Lett, 2025, 611: 217432.","journal-title":"Cancer Lett"},{"key":"CITATION47","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1158\/1078-0432.CCR-19-3249","volume":"26","author":"Zhang H","year":"2020","unstructured":"Zhang H, Liu L, Zhang J, Chen J, Ye J, Shukla S, Qiao J. Investigation of antigen-specific T-cell receptor clusters in human cancers. Clin Cancer Res, 2020, 26: 1359-1371.","journal-title":"Clin Cancer Res"},{"key":"CITATION48","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3724\/abbs.2023101","volume":"55","author":"Mu X","year":"2023","unstructured":"Mu X, Chen C, Dong L, Kang Z, Sun Z, Chen X, Zheng J. Immunotherapy in leukaemia. Acta Biochim Biophys Sin, 2023, 55: 974-987.","journal-title":"Acta Biochim Biophys Sin"},{"key":"CITATION49","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Zhao Z","year":"2015","unstructured":"Zhao Z, Condomines M, van der Stegen SJC, Perna F, Kloss CC, Gunset G, Plotkin J. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell, 2015, 28: 415-428.","journal-title":"Cancer Cell"},{"key":"CITATION50","doi-asserted-by":"publisher","first-page":"101023","DOI":"10.1016\/j.isci.2020.101023","volume":"23","author":"Rohrs JA","year":"2020","unstructured":"Rohrs JA, Siegler EL, Wang P, Finley SD. ERK activation in CAR T cells is amplified by CD28-Mediated increase in CD3\u03b6 phosphorylation. iScience, 2020, 23: 101023.","journal-title":"iScience"},{"key":"CITATION51","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41423-024-01198-y","volume":"21","author":"Dou Z","year":"2024","unstructured":"Dou Z, Bonacci TR, Shou P, Landoni E, Woodcock MG, Sun C, Savoldo B. 4-1BB-encoding CAR causes cell death via sequestration of the ubiquitin-modifying enzyme A20. Cell Mol Immunol, 2024, 21: 905-917.","journal-title":"Cell Mol Immunol"},{"key":"CITATION52","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"Kawalekar OU","year":"2016","unstructured":"Kawalekar OU, O\u2032Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey Jr. AD, Patel PR. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity, 2016, 44: 380-390.","journal-title":"Immunity"},{"key":"CITATION53","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1158\/2159-8290.CD-24-0096","volume":"14","author":"Acharya S","year":"2024","unstructured":"Acharya S, Basar R, Daher M, Rafei H, Li P, Uprety N, Ensley E. CD28 costimulation augments CAR signaling in NK cells via the LCK\/CD3\u03b6\/ZAP70 signaling axis. Cancer Discov, 2024, 14: 1879-1900.","journal-title":"Cancer Discov"},{"key":"CITATION54","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3390\/cancers13051050","volume":"13","author":"Textor A","year":"2021","unstructured":"Textor A, Grunewald L, Anders K, Klaus A, Schwiebert S, Winkler A, Stecklum M. CD28 co-stimulus achieves superior CAR T cell effector function against solid tumors than 4-1BB co-stimulus. Cancers, 2021, 13: 1050.","journal-title":"Cancers"},{"key":"CITATION55","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s42003-021-02119-9","volume":"4","author":"Lai YP","year":"2021","unstructured":"Lai YP, Kuo LC, Lin BR, Lin HJ, Lin CY, Chen YT, Hsiao PW. CD28 engagement inhibits CD73-mediated regulatory activity of CD8+ T cells. Commun Biol, 2021, 4: 595.","journal-title":"Commun Biol"},{"key":"CITATION56","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40164-025-00618-7","volume":"14","author":"Zhang P","year":"2025","unstructured":"Zhang P, Feng X, Niu X, Liu Z, Li M, Liu M, Yan D. CD28 is superior to 4-1BB costimulation in generating CAR-NK cells for tumor immunotherapy. Exp Hematol Oncol, 2025, 14: 28.","journal-title":"Exp Hematol Oncol"},{"key":"CITATION57","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1158\/2326-6066.CIR-24-0298","volume":"13","author":"Majocchi S","year":"2025","unstructured":"Majocchi S, Lloveras P, Nouveau L, Legrand M, Viandier A, Malinge P, Charreton M. NI-3201 is a bispecific antibody mediating PD-L1\u2013dependent CD28 co-stimulation on T cells for enhanced tumor control. Cancer Immunol Res, 2025, 13: 365-383.","journal-title":"Cancer Immunol Res"},{"key":"CITATION58","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.aaf0683","volume":"355","author":"Kamphorst AO","year":"2017","unstructured":"Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, Konieczny BT. Rescue of exhausted CD8 T cells by PD-1\u2013targeted therapies is CD28-dependent. Science, 2017, 355: 1423-1427.","journal-title":"Science"},{"key":"CITATION59","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41577-024-01061-1","volume":"24","author":"Lotze MT","year":"2024","unstructured":"Lotze MT, Olejniczak SH, Skokos D. CD28 co-stimulation: novel insights and applications in cancer immunotherapy. Nat Rev Immunol, 2024, 24: 878-895.","journal-title":"Nat Rev Immunol"},{"key":"CITATION60","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nm.4015","volume":"22","author":"Klebanoff CA","year":"2016","unstructured":"Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med, 2016, 22: 26-36.","journal-title":"Nat Med"},{"key":"CITATION61","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"Maude SL","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med, 2014, 371: 1507-1517.","journal-title":"N Engl J Med"},{"key":"CITATION62","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"Long AH","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med, 2015, 21: 581-590.","journal-title":"Nat Med"},{"key":"CITATION63","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"Maude SL","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med, 2018, 378: 439-448.","journal-title":"N Engl J Med"},{"key":"CITATION64","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"Schuster SJ","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, J\u00e4ger U. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med, 2019, 380: 45-56.","journal-title":"N Engl J Med"},{"key":"CITATION65","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/mt.2011.9","volume":"19","author":"Kofler DM","year":"2011","unstructured":"Kofler DM, Chmielewski M, Rappl G, Hombach A, Riet T, Schmidt A, Hombach AA. CD28 costimulation impairs the efficacy of a redirected T-cell antitumor attack in the presence of regulatory T cells which can be overcome by preventing lck activation. Mol Ther, 2011, 19: 760-767.","journal-title":"Mol Ther"},{"key":"CITATION66","doi-asserted-by":"publisher","first-page":"6772","DOI":"10.1182\/blood-2010-12-319780","volume":"118","author":"R\u00f6mer PS","year":"2011","unstructured":"R\u00f6mer PS, Berr S, Avota E, Na SY, Battaglia M, ten Berge I, Einsele H. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood, 2011, 118: 6772-6782.","journal-title":"Blood"},{"key":"CITATION67","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.3389\/fimmu.2018.01060","volume":"9","author":"Langenhorst D","year":"2018","unstructured":"Langenhorst D, Haack S, G\u00f6b S, Uri A, L\u00fchder F, Vanhove B, H\u00fcnig T. CD28 costimulation of T helper 1 cells enhances cytokine release in vivo. Front Immunol, 2018, 9: 1060.","journal-title":"Front Immunol"},{"key":"CITATION68","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1172\/JCI133215","volume":"130","author":"Guedan S","year":"2020","unstructured":"Guedan S, Madar A, Casado-Medrano V, Shaw C, Wing A, Liu F, Young RM. Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability. J Clin Invest, 2020, 130: 3087-3097.","journal-title":"J Clin Invest"},{"key":"CITATION69","doi-asserted-by":"publisher","first-page":"1456443","DOI":"10.3389\/fimmu.2024.1456443","volume":"15","author":"Wei C","year":"2024","unstructured":"Wei C, Huang X, Xu T, Fang Y, Wang F, He Q, Zhang P. NECTIN-4-redirected T cell antigen coupler T cells bearing CD28 show superior antitumor responses against solid tumors. Front Immunol, 2024, 15: 1456443.","journal-title":"Front Immunol"},{"key":"CITATION70","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/0008-5472.CAN-11-0422","volume":"71","author":"Song DG","year":"2011","unstructured":"Song DG, Ye Q, Carpenito C, Poussin M, Wang LP, Ji C, Figini M. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res, 2011, 71: 4617-4627.","journal-title":"Cancer Res"},{"key":"CITATION71","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1158\/1535-7163.MCT-19-0893","volume":"19","author":"Kotanides H","year":"2020","unstructured":"Kotanides H, Sattler RM, Lebron MB, Carpenito C, Shen J, Li J, Surguladze D. Characterization of 7A5: a human CD137 (4-1BB) receptor binding monoclonal antibody with differential agonist properties that promotes antitumor immunity. Mol Cancer Ther, 2020, 19: 988-998.","journal-title":"Mol Cancer Ther"},{"key":"CITATION72","doi-asserted-by":"publisher","first-page":"eaay8248","DOI":"10.1126\/scisignal.aay8248","volume":"13","author":"Philipson BI","year":"2020","unstructured":"Philipson BI, O\u2032Connor RS, May MJ, June CH, Albelda SM, Milone MC. 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-\u03baB signaling. Sci Signal, 2020, 13: eaay8248.","journal-title":"Sci Signal"},{"key":"CITATION73","doi-asserted-by":"publisher","first-page":"e16815","DOI":"10.1371\/journal.pone.0016815","volume":"6","author":"Ho JQ","year":"2011","unstructured":"Ho JQ, Asagiri M, Hoffmann A, Ghosh G, Agarwal S. NF-\u03baB potentiates caspase independent hydrogen peroxide induced cell death. PLoS ONE, 2011, 6: e16815.","journal-title":"PLoS ONE"},{"key":"CITATION74","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10495-018-1507-2","volume":"24","author":"Abhari BA","year":"2019","unstructured":"Abhari BA, McCarthy N, Agostinis P, Fulda S. NF-\u03baB contributes to Smac mimetic-conferred protection from tunicamycin-induced apoptosis. Apoptosis, 2019, 24: 269-277.","journal-title":"Apoptosis"},{"key":"CITATION75","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1091\/mbc.e10-06-0556","volume":"22","author":"Zhang L","year":"2011","unstructured":"Zhang L, Blackwell K, Altaeva A, Shi Z, Habelhah H, Luo K. TRAF2 phosphorylation promotes NF-\u03baB\u2013dependent gene expression and inhibits oxidative stress-induced cell death. Mol Biol Cell, 2011, 22: 128-140.","journal-title":"Mol Biol Cell"},{"key":"CITATION76","doi-asserted-by":"publisher","first-page":"25530","DOI":"10.1074\/jbc.M112.356279","volume":"287","author":"Liu F","year":"2012","unstructured":"Liu F, Bardhan K, Yang D, Thangaraju M, Ganapathy V, Waller JL, Liles GB. NF-\u03baB directly regulates fas transcription to modulate fas-mediated apoptosis and tumor suppression. J Biol Chem, 2012, 287: 25530-25540.","journal-title":"J Biol Chem"},{"key":"CITATION77","doi-asserted-by":"publisher","first-page":"eadd4671","DOI":"10.1126\/scisignal.add4671","volume":"17","author":"Ritmeester-Loy SA","year":"2024","unstructured":"Ritmeester-Loy SA, Draper IH, Bueter EC, Lautz JD, Zhang-Wong Y, Gustafson JA, Wilson AL. Differential protein-protein interactions underlie signaling mediated by the TCR and a 4-1BB domain\u2013containing CAR. Sci Signal, 2024, 17: eadd4671.","journal-title":"Sci Signal"},{"key":"CITATION78","doi-asserted-by":"publisher","first-page":"116439","DOI":"10.1016\/j.bcp.2024.116439","volume":"227","author":"Zhao W","year":"2024","unstructured":"Zhao W, Yao Y, Li Q, Xue Y, Gao X, Liu X, Zhang Q. Molecular mechanism of co-stimulatory domains in promoting CAR-T cell anti-tumor efficacy. Biochem Pharmacol, 2024, 227: 116439.","journal-title":"Biochem Pharmacol"},{"key":"CITATION79","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000492146","volume":"140","author":"Zhong Q","year":"2018","unstructured":"Zhong Q, Zhu Y, Zheng L, Shen H, Ou R, Liu Z, She Y. Chimeric antigen receptor-T cells with 4-1BB co-stimulatory domain present a superior treatment outcome than those with CD28 domain based on bioinformatics. Acta Haematol, 2018, 140: 131-140.","journal-title":"Acta Haematol"},{"key":"CITATION80","doi-asserted-by":"publisher","first-page":"hum.2022.068","DOI":"10.1089\/hum.2022.068","author":"Dunn ZS","year":"2023","unstructured":"Dunn ZS, Qu Y, MacMullan M, Chen X, Cinay G, Wang P. Secretion of 4-1BB ligand crosslinked to PD-1 checkpoint inhibitor potentiates chimeric antigen receptor T cell solid tumor efficacy. Hum Gene Ther, 2023, hum.2022.068.","journal-title":"Hum Gene Ther"},{"key":"CITATION81","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3390\/cancers14020299","volume":"14","author":"He Y","year":"2022","unstructured":"He Y, Vlaming M, van Meerten T, Bremer E. The implementation of TNFRSF co-stimulatory domains in CAR-T cells for optimal functional activity. Cancers, 2022, 14: 299.","journal-title":"Cancers"},{"key":"CITATION82","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1158\/0008-5472.CAN-20-2701","volume":"81","author":"Schoutrop E","year":"2021","unstructured":"Schoutrop E, El-Serafi I, Poiret T, Zhao Y, Gultekin O, He R, Moyano-Galceran L. Mesothelin-specific CAR T cells target ovarian cancer. Cancer Res, 2021, 81: 3022-3035.","journal-title":"Cancer Res"},{"key":"CITATION83","doi-asserted-by":"publisher","first-page":"e190841","DOI":"10.1172\/JCI190841","volume":"135","author":"Ahn J","year":"2025","unstructured":"Ahn J, Xie P, Chen S, Shi G, Fan J, Zhang M, Tang H. 4-1BB stimulation with concomitant inactivation of adenosine A2B receptors enhances CD8+ T cell antitumor response. J Clin Invest, 2025, 135: e190841.","journal-title":"J Clin Invest"},{"key":"CITATION84","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41591-021-01326-5","volume":"27","author":"Singh N","year":"2021","unstructured":"Singh N, Frey NV, Engels B, Barrett DM, Shestova O, Ravikumar P, Cummins KD. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. Nat Med, 2021, 27: 842-850.","journal-title":"Nat Med"},{"key":"CITATION85","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s43018-023-00573-4","volume":"4","author":"Xiong Y","year":"2023","unstructured":"Xiong Y, Taleb M, Misawa K, Hou Z, Banerjee S, Amador-Molina A, Jones DR. c-Kit signaling potentiates CAR T cell efficacy in solid tumors by CD28- and IL-2-independent co-stimulation. Nat Cancer, 2023, 4: 1001-1015.","journal-title":"Nat Cancer"},{"key":"CITATION86","doi-asserted-by":"publisher","first-page":"e000629","DOI":"10.1136\/esmoopen-2019-000629","volume":"4","author":"Starzer AM","year":"2020","unstructured":"Starzer AM, Berghoff AS. New emerging targets in cancer immunotherapy: CD27 (TNFRSF7). ESMO Open, 2020, 4: e000629.","journal-title":"ESMO Open"},{"key":"CITATION87","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1182\/blood-2011-03-344275","volume":"119","author":"Song DG","year":"2012","unstructured":"Song DG, Ye Q, Poussin M, Harms GM, Figini M, Powell Jr DJ. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood, 2012, 119: 696-706.","journal-title":"Blood"},{"key":"CITATION88","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2217\/imt.15.32","volume":"7","author":"van de Ven K","year":"2015","unstructured":"van de Ven K, Borst J. Targeting the T-cell co-stimulatory CD27\/CD70 pathway in cancer immunotherapy: rationale and potential. Immunotherapy, 2015, 7: 655-667.","journal-title":"Immunotherapy"},{"key":"CITATION89","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.immuni.2024.01.011","volume":"57","author":"Jaeger-Ruckstuhl CA","year":"2024","unstructured":"Jaeger-Ruckstuhl CA, Lo Y, Fulton E, Waltner OG, Shabaneh TB, Simon S, Muthuraman PV. Signaling via a CD27-TRAF2-SHP-1 axis during naive T cell activation promotes memory-associated gene regulatory networks. Immunity, 2024, 57: 287-302.e12.","journal-title":"Immunity"},{"key":"CITATION90","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1093\/jimmun\/vkaf075","volume":"214","author":"Tran Ngoc Minh T","year":"2025","unstructured":"Tran Ngoc Minh T, Verleng LJ, Schrama E, Busselaar J, Staal MD, de Vries E, Anholts JDH. CD27 costimulation supports metabolic fitness of CD4+ T cells by enhancing de novo nucleotide and protein synthesis. J Immunol, 2025, 214: 1566-1581.","journal-title":"J Immunol"},{"key":"CITATION91","doi-asserted-by":"publisher","first-page":"6670","DOI":"10.4049\/jimmunol.1000159","volume":"185","author":"Peperzak V","year":"2010","unstructured":"Peperzak V, Veraar EAM, Keller AM, Xiao Y, Borst J. The pim kinase pathway contributes to survival signaling in primed CD8+ T Cells upon CD27 costimulation. J Immunol, 2010, 185: 6670-6678.","journal-title":"J Immunol"},{"key":"CITATION92","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s12032-023-01959-1","volume":"40","author":"Zhang C","year":"2023","unstructured":"Zhang C, Jia J, Heng G, Li Y, Wang M, Chen J, Wang L. CD27 agonism coordinates with CD28 and 4-1BB signal to augment the efficacy of CAR-T cells in colorectal tumor. Med Oncol, 2023, 40: 123.","journal-title":"Med Oncol"},{"key":"CITATION93","doi-asserted-by":"publisher","first-page":"e27255","DOI":"10.4161\/onci.27255","volume":"3","author":"Thomas LJ","year":"2014","unstructured":"Thomas LJ, He LZ, Marsh H, Keler T. Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity. OncoImmunology, 2014, 3: e27255.","journal-title":"OncoImmunology"},{"key":"CITATION94","doi-asserted-by":"publisher","first-page":"1191866","DOI":"10.3389\/fimmu.2023.1191866","volume":"14","author":"Melo V","year":"2023","unstructured":"Melo V, Nelemans LC, Vlaming M, Lourens HJ, Wiersma VR, Bilemjian V, Huls G. EGFR-selective activation of CD27 co-stimulatory signaling by a bispecific antibody enhances anti-tumor activity of T cells. Front Immunol, 2023, 14: 1191866.","journal-title":"Front Immunol"},{"key":"CITATION95","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1158\/0008-5472.CAN-11-2791","volume":"72","author":"Claus C","year":"2012","unstructured":"Claus C, Riether C, Sch\u00fcrch C, Matter MS, Hilmenyuk T, Ochsenbein AF. CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth. Cancer Res, 2012, 72: 3664-3676.","journal-title":"Cancer Res"},{"key":"CITATION96","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.immuni.2016.04.019","volume":"44","author":"Ward-Kavanagh LK","year":"2016","unstructured":"Ward-Kavanagh LK, Lin WW, \u0160ed\u00fd JR, Ware CF. The TNF receptor superfamily in co-stimulating and co-inhibitory responses. Immunity, 2016, 44: 1005-1019.","journal-title":"Immunity"},{"key":"CITATION97","doi-asserted-by":"publisher","first-page":"6198","DOI":"10.1073\/pnas.092576699","volume":"99","author":"Khayyamian S","year":"2002","unstructured":"Khayyamian S, Hutloff A, B\u00fcchner K, Gr\u00e4fe M, Henn V, Kroczek RA, Mages HW. ICOS-ligand, expressed on human endothelial cells, costimulates Th1 and Th2 cytokine secretion by memory CD4+ T cells. Proc Natl Acad Sci USA, 2002, 99: 6198-6203.","journal-title":"Proc Natl Acad Sci USA"},{"key":"CITATION98","doi-asserted-by":"publisher","first-page":"9581","DOI":"10.1158\/0008-5472.CAN-10-1379","volume":"70","author":"Martin-Orozco N","year":"2010","unstructured":"Martin-Orozco N, Li Y, Wang Y, Liu S, Hwu P, Liu YJ, Dong C. Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. Cancer Res, 2010, 70: 9581-9590.","journal-title":"Cancer Res"},{"key":"CITATION99","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.4049\/jimmunol.181.3.1969","volume":"181","author":"Fos C","year":"2008","unstructured":"Fos C, Salles A, Lang V, Carrette F, Audebert S, Pastor S, Ghiotto M. ICOS ligation recruits the p50\u03b1 PI3K regulatory subunit to the immunological synapse. J Immunol, 2008, 181: 1969-1977.","journal-title":"J Immunol"},{"key":"CITATION100","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1158\/2326-6066.CIR-13-0155","volume":"2","author":"Chen H","year":"2014","unstructured":"Chen H, Fu T, Suh WK, Tsavachidou D, Wen S, Gao J, Ng Tang D. CD4 T cells require ICOS-mediated PI3K signaling to increase T-bet expression in the setting of anti-CTLA-4 therapy. Cancer Immunol Res, 2014, 2: 167-176.","journal-title":"Cancer Immunol Res"},{"key":"CITATION101","doi-asserted-by":"publisher","first-page":"e000544","DOI":"10.1136\/esmoopen-2019-000544","volume":"5","author":"Solinas C","year":"2020","unstructured":"Solinas C, Gu-Trantien C, Willard-Gallo K. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy. ESMO Open, 2020, 5: e000544.","journal-title":"ESMO Open"},{"key":"CITATION102","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12885-023-10564-4","volume":"23","author":"Zhao X","year":"2023","unstructured":"Zhao X, Wang Y, Jiang X, Mo B, Wang C, Tang M, Rong Y. Comprehensive analysis of the role of ICOS (CD278) in pan-cancer prognosis and immunotherapy. BMC Cancer, 2023, 23: 194.","journal-title":"BMC Cancer"},{"key":"CITATION103","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1084\/jem.20130590","volume":"211","author":"Fan X","year":"2014","unstructured":"Fan X, Quezada SA, Sepulveda MA, Sharma P, Allison JP. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med, 2014, 211: 715-725.","journal-title":"J Exp Med"},{"key":"CITATION104","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.intimp.2018.10.045","volume":"66","author":"Zhang M","year":"2019","unstructured":"Zhang M, Xia L, Yang Y, Liu S, Ji P, Wang S, Chen Y. PD-1 blockade augments humoral immunity through ICOS-mediated CD4+ T cell instruction. Int Immunopharmacol, 2019, 66: 127-138.","journal-title":"Int Immunopharmacol"},{"key":"CITATION105","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1158\/0008-5472.CAN-19-3265","volume":"80","author":"Xiao Z","year":"2020","unstructured":"Xiao Z, Mayer AT, Nobashi TW, Gambhir SS. ICOS is an indicator of T-cell\u2013mediated response to cancer immunotherapy. Cancer Res, 2020, 80: 3023-3032.","journal-title":"Cancer Res"},{"key":"CITATION106","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/j.ymthe.2019.07.013","volume":"27","author":"Soldevilla MM","year":"2019","unstructured":"Soldevilla MM, Villanueva H, Meraviglia-Crivelli D, Menon AP, Ruiz M, Cebollero J, Villalba M. ICOS costimulation at the tumor site in combination with CTLA-4 blockade therapy elicits strong tumor immunity. Mol Ther, 2019, 27: 1878-1891.","journal-title":"Mol Ther"},{"key":"CITATION107","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1093\/jimmun\/vkaf040","volume":"214","author":"Luo Y","year":"2025","unstructured":"Luo Y, Li H, Fang H, Gong T, Zhao Y, Cao W, Yu M. ICOS+ CD4+ T cells promote antitumor immunity through Akt\/STAT1\/T-bet axis in MSS\/pMMR colorectal cancer. J Immunol, 2025, 214: 1422-1433.","journal-title":"J Immunol"},{"key":"CITATION108","doi-asserted-by":"publisher","first-page":"e96976","DOI":"10.1172\/jci.insight.96976","volume":"3","author":"Guedan S","year":"2018","unstructured":"Guedan S, Posey Jr. AD, Shaw C, Wing A, Da T, Patel PR, McGettigan SE. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight, 2018, 3: e96976.","journal-title":"JCI Insight"},{"key":"CITATION109","doi-asserted-by":"publisher","first-page":"e011564","DOI":"10.1136\/jitc-2025-011564","volume":"13","author":"Herbrich S","year":"2025","unstructured":"Herbrich S, Chaib M, Sharma P. ICOS-expressing CAR-T cells mediate durable eradication of triple-negative breast cancer and metastasis. J Immunother Cancer, 2025, 13: e011564.","journal-title":"J Immunother Cancer"},{"key":"CITATION110","doi-asserted-by":"publisher","first-page":"1200914","DOI":"10.3389\/fonc.2023.1200914","volume":"13","author":"Moreno-Cortes E","year":"2023","unstructured":"Moreno-Cortes E, Franco-Fuquen P, Garcia-Robledo JE, Forero J, Booth N, Castro JE. ICOS and OX40 tandem co-stimulation enhances CAR T-cell cytotoxicity and promotes T-cell persistence phenotype. Front Oncol, 2023, 13: 1200914.","journal-title":"Front Oncol"},{"key":"CITATION111","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.jcyt.2021.02.117","volume":"23","author":"Wang Y","year":"2021","unstructured":"Wang Y, Zhong K, Ke J, Chen X, Chen Y, Shu W, Chen C. Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19\/CD20 chimeric antigen receptor T cells. Cytotherapy, 2021, 23: 715-723.","journal-title":"Cytotherapy"},{"key":"CITATION112","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1158\/2326-6066.CIR-22-0531","volume":"11","author":"Sun S","year":"2023","unstructured":"Sun S, Huang C, Lu M, Xu H, Yuan Y, Zhao W, Hu X. Herpes virus entry mediator costimulation signaling enhances CAR T-cell efficacy against solid tumors through metabolic reprogramming. Cancer Immunol Res, 2023, 11: 515-529.","journal-title":"Cancer Immunol Res"},{"key":"CITATION113","doi-asserted-by":"publisher","first-page":"e167215","DOI":"10.1172\/jci.insight.167215","volume":"8","author":"Rosado-S\u00e1nchez I","year":"2023","unstructured":"Rosado-S\u00e1nchez I, Haque M, Salim K, Speck M, Fung VCW, Boardman DA, Mojibian M. Tregs integrate native and CAR-mediated costimulatory signals for control of allograft rejection. JCI Insight, 2023, 8: e167215.","journal-title":"JCI Insight"},{"key":"CITATION114","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41423-021-00655-2","volume":"18","author":"Liu G","year":"2021","unstructured":"Liu G, Rui W, Zhao X, Lin X. Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment. Cell Mol Immunol, 2021, 18: 1085-1095.","journal-title":"Cell Mol Immunol"},{"key":"CITATION115","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.21037\/atm-20-7342","volume":"8","author":"Zhong Z","year":"2020","unstructured":"Zhong Z, Zhang Q, Tan L, Guo X, Gan C. T cell co-stimulator inducible co-stimulatory (ICOS) exerts potential anti-atherosclerotic roles through downregulation of vascular smooth muscle phagocytosis and proliferation. Ann Transl Med, 2020, 8: 1597.","journal-title":"Ann Transl Med"},{"key":"CITATION116","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40364-023-00508-2","volume":"11","author":"Ralser DJ","year":"2023","unstructured":"Ralser DJ, Herr E, de Vos L, Kulcs\u00e1r Z, Zarbl R, Kl\u00fcmper N, Gielen GH. ICOS DNA methylation regulates melanoma cell-intrinsic ICOS expression, is associated with melanoma differentiation, prognosis, and predicts response to immune checkpoint blockade. Biomark Res, 2023, 11: 56.","journal-title":"Biomark Res"},{"key":"CITATION117","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1615\/CritRevImmunol.v29.i3.10","volume":"29","author":"Redmond WL","year":"2009","unstructured":"Redmond WL, Ruby CE, Weinberg AD. The role of OX40-mediated co-stimulation in T-cell activation and survival. Crit Rev Immunol, 2009, 29: 187-201.","journal-title":"Crit Rev Immunol"},{"key":"CITATION118","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1002\/eji.200939448","volume":"39","author":"Redmond WL","year":"2009","unstructured":"Redmond WL, Gough MJ, Weinberg AD. Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo. Eur J Immunol, 2009, 39: 2184-2194.","journal-title":"Eur J Immunol"},{"key":"CITATION119","doi-asserted-by":"publisher","first-page":"eaba7308","DOI":"10.1126\/scitranslmed.aba7308","volume":"13","author":"Zhang H","year":"2021","unstructured":"Zhang H, Li F, Cao J, Wang X, Cheng H, Qi K, Wang G. A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity. Sci Transl Med, 2021, 13: eaba7308.","journal-title":"Sci Transl Med"},{"key":"CITATION120","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-022-01244-0","volume":"15","author":"Tan J","year":"2022","unstructured":"Tan J, Jia Y, Zhou M, Fu C, Tuhin IJ, Ye J, Monty MA. Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells. J Hematol Oncol, 2022, 15: 39.","journal-title":"J Hematol Oncol"},{"key":"CITATION121","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3324\/haematol.2019.231183","volume":"106","author":"Guercio M","year":"2021","unstructured":"Guercio M, Orlando D, Di Cecca S, Sinibaldi M, Boffa I, Caruso S, Abbaszadeh Z. CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells. Haematologica, 2021, 106: 987-999.","journal-title":"Haematologica"},{"key":"CITATION122","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1002\/ijc.25960","volume":"129","author":"Hombach AA","year":"2011","unstructured":"Hombach AA, Abken H. Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling. Intl J Cancer, 2011, 129: 2935-2944.","journal-title":"Intl J Cancer"},{"key":"CITATION123","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4161\/onci.19855","volume":"1","author":"Hombach AA","year":"2012","unstructured":"Hombach AA, Heiders J, Foppe M, Chmielewski M, Abken H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells. OncoImmunology, 2012, 1: 458-466.","journal-title":"OncoImmunology"},{"key":"CITATION124","doi-asserted-by":"publisher","first-page":"e009476","DOI":"10.1136\/jitc-2024-009476","volume":"12","author":"Wang T","year":"2024","unstructured":"Wang T, Yang Y, Ma L, Feng R, Li J, Zhang C, Bai J. BCMA-BBZ-OX40 CAR-T therapy using an instant manufacturing platform in multiple myeloma. J Immunother Cancer, 2024, 12: e009476.","journal-title":"J Immunother Cancer"},{"key":"CITATION125","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00428-022-03348-x","volume":"481","author":"Ghosh A","year":"2022","unstructured":"Ghosh A, Marques-Piubelli ML, Wang X, Sheu TG, Cheng J, Khan K, Lu W. CD2-negative lymphoma-associated T-cells: a potential mechanism of immune-evasion in diffuse large B-cell lymphoma. Virchows Arch, 2022, 481: 659-663.","journal-title":"Virchows Arch"},{"key":"CITATION126","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.4049\/jimmunol.1101804","volume":"187","author":"Kalland ME","year":"2011","unstructured":"Kalland ME, Oberprieler NG, Vang T, Task\u00e9n K, Torgersen KM. T cell-signaling network analysis reveals distinct differences between CD28 and CD2 costimulation responses in various subsets and in the MAPK pathway between resting and activated regulatory T cells. J Immunol, 2011, 187: 5233-5245.","journal-title":"J Immunol"},{"key":"CITATION127","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/gt.2011.192","volume":"19","author":"Cheadle EJ","year":"2012","unstructured":"Cheadle EJ, Rothwell DG, Bridgeman JS, Sheard VE, Hawkins RE, Gilham DE. Ligation of the CD2 co-stimulatory receptor enhances IL-2 production from first-generation chimeric antigen receptor T cells. Gene Ther, 2012, 19: 1114-1120.","journal-title":"Gene Ther"},{"key":"CITATION128","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1600-6143.2010.03317.x","volume":"11","author":"Lo DJ","year":"2011","unstructured":"Lo DJ, Weaver TA, Stempora L, Mehta AK, Ford ML, Larsen CP, Kirk AD. Selective targeting of human alloresponsive CD8+ Effector memory T cells based on CD2 expression. Am J Transplant, 2011, 11: 22-33.","journal-title":"Am J Transplant"},{"key":"CITATION129","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1038\/s41375-023-02039-z","volume":"37","author":"Xiang J","year":"2023","unstructured":"Xiang J, Devenport JM, Carter AJ, Staser KW, Kim MY, O\u2019 Neal J, Ritchey JK. An \u201coff-the-shelf\u201d CD2 universal CAR-T therapy for T-cell malignancies. Leukemia, 2023, 37: 2448-2456.","journal-title":"Leukemia"},{"key":"CITATION130","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1080\/14728222.2018.1512588","volume":"22","author":"Riccardi C","year":"2018","unstructured":"Riccardi C, Ronchetti S, Nocentini G. Glucocorticoid-induced TNFR-related gene (GITR) as a therapeutic target for immunotherapy. Expert Opin Ther Targets, 2018, 22: 783-797.","journal-title":"Expert Opin Ther Targets"},{"key":"CITATION131","doi-asserted-by":"publisher","first-page":"e000738","DOI":"10.1136\/esmoopen-2020-000738","volume":"4","author":"Buzzatti G","year":"2020","unstructured":"Buzzatti G, Dellepiane C, Del Mastro L. New emerging targets in cancer immunotherapy: the role of GITR. ESMO Open, 2020, 4: e000738.","journal-title":"ESMO Open"},{"key":"CITATION132","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3390\/biom12091303","volume":"12","author":"Honikel MM","year":"2022","unstructured":"Honikel MM, Olejniczak SH. Co-stimulatory receptor signaling in CAR-T cells. Biomolecules, 2022, 12: 1303.","journal-title":"Biomolecules"},{"key":"CITATION133","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41434-021-00257-7","volume":"30","author":"Liang X","year":"2023","unstructured":"Liang X, Huang Y, Li D, Yang X, Jiang L, Zhou W, Su J. Distinct functions of CAR-T cells possessing a dectin-1 intracellular signaling domain. Gene Ther, 2023, 30: 411-420.","journal-title":"Gene Ther"},{"key":"CITATION134","doi-asserted-by":"publisher","first-page":"107604","DOI":"10.1016\/j.phrs.2025.107604","volume":"213","author":"Yao Y","year":"2025","unstructured":"Yao Y, Li B, Chen C, Wang J, Yao F, Li Z. HVEM as a tumor-intrinsic regulator in non-small cell lung cancer: suppression of metastasis via glycolysis inhibition and modulation of macrophage polarization. Pharmacol Res, 2025, 213: 107604.","journal-title":"Pharmacol Res"},{"key":"CITATION135","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.imlet.2013.01.008","volume":"151","author":"Pasero C","year":"2013","unstructured":"Pasero C, Olive D. Interfering with coinhibitory molecules: BTLA\/HVEM as new targets to enhance anti-tumor immunity. Immunol Lett, 2013, 151: 71-75.","journal-title":"Immunol Lett"},{"key":"CITATION136","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/s41590-024-01847-4","volume":"25","author":"Guruprasad P","year":"2024","unstructured":"Guruprasad P, Carturan A, Zhang Y, Cho JH, Kumashie KG, Patel RP, Kim KH. The BTLA\u2013HVEM axis restricts CAR T cell efficacy in cancer. Nat Immunol, 2024, 25: 1020-1032.","journal-title":"Nat Immunol"},{"key":"CITATION137","doi-asserted-by":"publisher","first-page":"8662","DOI":"10.3390\/ijms25168662","volume":"25","author":"Nunoya J","year":"2024","unstructured":"Nunoya J, Imuta N, Masuda M. Chimeric antigen receptor T cell bearing herpes virus entry mediator co-stimulatory signal domain exhibits exhaustion-resistant properties. Int J Mol Sci, 2024, 25: 8662.","journal-title":"Int J Mol Sci"},{"key":"CITATION138","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.omto.2019.03.002","volume":"14","author":"Nunoya J","year":"2019","unstructured":"Nunoya J, Masuda M, Ye C, Su L. Chimeric antigen receptor T cell bearing herpes virus entry mediator co-stimulatory signal domain exhibits high functional potency. Mol Ther Oncolytics, 2019, 14: 27-37.","journal-title":"Mol Ther Oncolytics"},{"key":"CITATION139","doi-asserted-by":"publisher","DOI":"10.3724\/abbs.2025071","author":"Yuan H","year":"2025","unstructured":"Yuan H, Zhu L, Yang L, Yi Y, Lv T. CD47-mediated tumor microenvironment remodeling: a central mechanism in immune evasion. Acta Biochim Biophys Sin, 2025.","journal-title":"Acta Biochim Biophys Sin"},{"key":"CITATION140","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri.2017.49","volume":"17","author":"Nagarsheth N","year":"2017","unstructured":"Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol, 2017, 17: 559-572.","journal-title":"Nat Rev Immunol"},{"key":"CITATION141","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41571-018-0007-1","volume":"15","author":"Valkenburg KC","year":"2018","unstructured":"Valkenburg KC, de Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol, 2018, 15: 366-381.","journal-title":"Nat Rev Clin Oncol"},{"key":"CITATION142","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.coi.2015.01.011","volume":"33","author":"Lanitis E","year":"2015","unstructured":"Lanitis E, Irving M, Coukos G. Targeting the tumor vasculature to enhance T cell activity. Curr Opin Immunol, 2015, 33: 55-63.","journal-title":"Curr Opin Immunol"},{"key":"CITATION143","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2017.145","volume":"18","author":"Huang Y","year":"2018","unstructured":"Huang Y, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W. Improving immune\u2013vascular crosstalk for cancer immunotherapy. Nat Rev Immunol, 2018, 18: 195-203.","journal-title":"Nat Rev Immunol"},{"key":"CITATION144","doi-asserted-by":"publisher","first-page":"188701","DOI":"10.1016\/j.bbcan.2022.188701","volume":"1877","author":"Akbari P","year":"2022","unstructured":"Akbari P, Katsarou A, Daghighian R, van Mil LWHG, Huijbers EJM, Griffioen AW, van Beijnum JR. Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors. Biochim Biophys Acta Rev Cancer, 2022, 1877: 188701.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"CITATION145","doi-asserted-by":"publisher","first-page":"738456","DOI":"10.3389\/fimmu.2021.738456","volume":"12","author":"Ghahri-Saremi N","year":"2021","unstructured":"Ghahri-Saremi N, Akbari B, Soltantoyeh T, Hadjati J, Ghassemi S, Mirzaei HR. Genetic modification of cytokine signaling to enhance efficacy of CAR T cell therapy in solid tumors. Front Immunol, 2021, 12: 738456.","journal-title":"Front Immunol"},{"key":"CITATION146","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","volume":"17","author":"Moon EK","year":"2011","unstructured":"Moon EK, Carpenito C, Sun J, Wang LCS, Kapoor V, Predina J, Powell Jr. DJ. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res, 2011, 17: 4719-4730.","journal-title":"Clin Cancer Res"},{"key":"CITATION147","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cytogfr.2017.06.006","volume":"36","author":"Mondino A","year":"2017","unstructured":"Mondino A, Vella G, Icardi L. Targeting the tumor and its associated stroma: one and one can make three in adoptive T cell therapy of solid tumors. Cytokine Growth Factor Rev, 2017, 36: 57-65.","journal-title":"Cytokine Growth Factor Rev"},{"key":"CITATION148","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1016\/j.ymthe.2021.02.004","volume":"29","author":"McKenna MK","year":"2021","unstructured":"McKenna MK, Englisch A, Brenner B, Smith T, Hoyos V, Suzuki M, Brenner MK. Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity. Mol Ther, 2021, 29: 1808-1820.","journal-title":"Mol Ther"},{"key":"CITATION149","doi-asserted-by":"publisher","first-page":"124558","DOI":"10.1016\/j.ijpharm.2024.124558","volume":"663","author":"Liu C","year":"2024","unstructured":"Liu C, Wang Q, Li L, Gao F, Zhang Y, Zhu Y. The peptide-based bispecific CAR T cells target EGFR and tumor stroma for effective cancer therapy. Int J Pharm, 2024, 663: 124558.","journal-title":"Int J Pharm"},{"key":"CITATION150","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41392-024-01824-1","volume":"9","author":"Fu R","year":"2024","unstructured":"Fu R, Qi R, Xiong H, Lei X, Jiang Y, He J, Chen F. Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects. Sig Transduct Target Ther, 2024, 9: 118.","journal-title":"Sig Transduct Target Ther"},{"key":"CITATION151","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.3390\/cancers12092626","volume":"12","author":"Wang Y","year":"2020","unstructured":"Wang Y, Jia A, Bi Y, Wang Y, Yang Q, Cao Y, Li Y. Targeting myeloid-derived suppressor cells in cancer immunotherapy. Cancers, 2020, 12: 2626.","journal-title":"Cancers"},{"key":"CITATION152","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1158\/0008-5472.CAN-20-1885","volume":"81","author":"La Fleur L","year":"2021","unstructured":"La Fleur L, Botling J, He F, Pelicano C, Zhou C, He C, Palano G. Targeting MARCO and IL37R on immunosuppressive macrophages in lung cancer blocks regulatory T cells and supports cytotoxic lymphocyte function. Cancer Res, 2021, 81: 956-967.","journal-title":"Cancer Res"},{"key":"CITATION153","doi-asserted-by":"publisher","first-page":"e10681","DOI":"10.15252\/emmm.201910681","volume":"12","author":"Germann M","year":"2020","unstructured":"Germann M, Zangger N, Sauvain MO, Sempoux C, Bowler AD, Wirapati P, Kandalaft LE. Neutrophils suppress tumor-infiltrating T cells in colon cancer via matrix metalloproteinase-mediated activation of TGF \u03b2. EMBO Mol Med, 2020, 12: e10681.","journal-title":"EMBO Mol Med"},{"key":"CITATION154","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.immuni.2019.06.017","volume":"51","author":"Liu C","year":"2019","unstructured":"Liu C, Chikina M, Deshpande R, Menk AV, Wang T, Tabib T, Brunazzi EA. Treg cells promote the SREBP1-dependent metabolic fitness of tumor-promoting macrophages via repression of CD8+ T cell-derived interferon-\u03b3. Immunity, 2019, 51: 381-397.e6.","journal-title":"Immunity"},{"key":"CITATION155","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.3390\/cells11223626","volume":"11","author":"Cheever A","year":"2022","unstructured":"Cheever A, Townsend M, O\u2019Neill K. Tumor microenvironment immunosuppression: a roadblock to CAR T-cell advancement in solid tumors. Cells, 2022, 11: 3626.","journal-title":"Cells"},{"key":"CITATION156","doi-asserted-by":"publisher","first-page":"12837","DOI":"10.3390\/ijms241612837","volume":"24","author":"Farooq MA","year":"2023","unstructured":"Farooq MA, Ajmal I, Hui X, Chen Y, Ren Y, Jiang W. \u03b22-Adrenergic receptor mediated inhibition of T cell function and its implications for CAR-T cell therapy. Int J Mol Sci, 2023, 24: 12837.","journal-title":"Int J Mol Sci"},{"key":"CITATION157","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1038\/s41467-019-11893-4","volume":"10","author":"Zou F","year":"2019","unstructured":"Zou F, Lu L, Liu J, Xia B, Zhang W, Hu Q, Liu W. Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56. Nat Commun, 2019, 10: 4109.","journal-title":"Nat Commun"},{"key":"CITATION158","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.ymthe.2024.12.014","volume":"33","author":"Zheng S","year":"2025","unstructured":"Zheng S, Che X, Zhang K, Bai Y, Deng H. Potentiating CAR-T cell function in the immunosuppressive tumor microenvironment by inverting the TGF-\u03b2 signal. Mol Ther, 2025, 33: 688-702.","journal-title":"Mol Ther"},{"key":"CITATION159","doi-asserted-by":"publisher","first-page":"e2102624","DOI":"10.1002\/smll.202102624","volume":"17","author":"Zhu L","year":"2021","unstructured":"Zhu L, Liu J, Zhou G, Liu TM, Dai Y, Nie G, Zhao Q. Remodeling of tumor microenvironment by tumor-targeting nanozymes enhances immune activation of CAR T cells for combination therapy. Small, 2021, 17: e2102624.","journal-title":"Small"},{"key":"CITATION160","doi-asserted-by":"publisher","first-page":"9111","DOI":"10.1039\/D4TB00769G","volume":"12","author":"Xu X","year":"2024","unstructured":"Xu X, Zhang Y, Meng C, Zheng W, Wang L, Zhao C, Luo F. Nanozymes in cancer immunotherapy: metabolic disruption and therapeutic synergy. J Mater Chem B, 2024, 12: 9111-9143.","journal-title":"J Mater Chem B"},{"key":"CITATION161","doi-asserted-by":"publisher","first-page":"1518983","DOI":"10.3389\/fphar.2024.1518983","volume":"15","author":"Yang Q","year":"2024","unstructured":"Yang Q, Wu Q, Liu H, Wu J, Ma F, Tian X. Tumor microenvironment\u2013responsive and modulatory manganese-based nanoenzyme for enhanced tumor immunotherapy. Front Pharmacol, 2024, 15: 1518983.","journal-title":"Front Pharmacol"},{"key":"CITATION162","doi-asserted-by":"publisher","first-page":"e2401299","DOI":"10.1002\/smll.202401299","volume":"20","author":"Wu W","year":"2024","unstructured":"Wu W, Li H, Chen W, Hu Y, Wang Z, She W, Huang L. CAR T cell membrane camouflaged nanocatalyst augments CAR T cell therapy efficacy against solid tumor. Small, 2024, 20: e2401299.","journal-title":"Small"},{"key":"CITATION163","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/j.ymthe.2021.02.024","volume":"29","author":"Murad JP","year":"2021","unstructured":"Murad JP, Tilakawardane D, Park AK, Lopez LS, Young CA, Gibson J, Yamaguchi Y. Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity. Mol Ther, 2021, 29: 2335-2349.","journal-title":"Mol Ther"},{"key":"CITATION164","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.tcb.2024.11.010","volume":"35","author":"Wang X","year":"2025","unstructured":"Wang X, Fan R, Mu M, Zhou L, Zou B, Tong A, Guo G. Harnessing nanoengineered CAR-T cell strategies to advance solid tumor immunotherapy. Trends Cell Biol, 2025, 35: 782-798.","journal-title":"Trends Cell Biol"},{"key":"CITATION165","doi-asserted-by":"publisher","first-page":"eabn6563","DOI":"10.1126\/sciimmunol.abn6563","volume":"7","author":"Delfanti G","year":"2022","unstructured":"Delfanti G, Cortesi F, Perini A, Antonini G, Azzimonti L, de Lalla C, Garavaglia C. TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells. Sci Immunol, 2022, 7: eabn6563.","journal-title":"Sci Immunol"},{"key":"CITATION166","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","volume":"22","author":"Scharping NE","year":"2021","unstructured":"Scharping NE, Rivadeneira DB, Menk AV, Vignali PDA, Ford BR, Rittenhouse NL, Peralta R. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol, 2021, 22: 205-215.","journal-title":"Nat Immunol"},{"key":"CITATION167","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.3389\/fimmu.2020.01906","volume":"11","author":"Liu YN","year":"2020","unstructured":"Liu YN, Yang JF, Huang DJ, Ni HH, Zhang CX, Zhang L, He J. Hypoxia induces mitochondrial defect that promotes T cell exhaustion in tumor microenvironment through MYC-regulated pathways. Front Immunol, 2020, 11: 1906.","journal-title":"Front Immunol"},{"key":"CITATION168","doi-asserted-by":"publisher","first-page":"e24411","DOI":"10.1371\/journal.pone.0024411","volume":"6","author":"Frezza C","year":"2011","unstructured":"Frezza C, Zheng L, Tennant DA, Papkovsky DB, Hedley BA, Kalna G, Watson DG. Metabolic profiling of hypoxic cells revealed a catabolic signature required for cell survival. PLoS One, 2011, 6: e24411.","journal-title":"PLoS One"},{"key":"CITATION169","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40364-020-00238-9","volume":"8","author":"Liao Q","year":"2020","unstructured":"Liao Q, He H, Mao Y, Ding X, Zhang X, Xu J. Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing. Biomark Res, 2020, 8: 56.","journal-title":"Biomark Res"},{"key":"CITATION170","doi-asserted-by":"publisher","first-page":"e177141","DOI":"10.1172\/jci.insight.177141","volume":"9","author":"Hatae R","year":"2024","unstructured":"Hatae R, Kyewalabye K, Yamamichi A, Chen T, Phyu S, Chuntova P, Nejo T. Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment. JCI Insight, 2024, 9: e177141.","journal-title":"JCI Insight"},{"key":"CITATION171","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.3390\/ijms22052476","volume":"22","author":"Fujiwara K","year":"2021","unstructured":"Fujiwara K, Kitaura M, Tsunei A, Kusabuka H, Ogaki E, Okada N. Structure of the signal transduction domain in second-generation CAR regulates the input efficiency of CAR signals. Int J Mol Sci, 2021, 22: 2476.","journal-title":"Int J Mol Sci"},{"key":"CITATION172","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/s41590-020-0719-0","volume":"21","author":"Gudipati V","year":"2020","unstructured":"Gudipati V, Rydzek J, Doel-Perez I, Gon\u00e7alves VDR, Scharf L, K\u00f6nigsberger S, Lobner E. Inefficient CAR-proximal signaling blunts antigen sensitivity. Nat Immunol, 2020, 21: 848-856.","journal-title":"Nat Immunol"},{"key":"CITATION173","doi-asserted-by":"publisher","first-page":"e010208","DOI":"10.1136\/jitc-2024-010208","volume":"12","author":"Barden M","year":"2024","unstructured":"Barden M, Elsenbroich PR, Haas V, Ertelt M, Pervan P, Velas L, Gergely B. Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function. J Immunother Cancer, 2024, 12: e010208.","journal-title":"J Immunother Cancer"},{"key":"CITATION174","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.ccell.2025.02.008","volume":"43","author":"Pham-Danis C","year":"2025","unstructured":"Pham-Danis C, Novak AJ, Danis E, McClellan SM, Leach L, Yarnell MC, Ebmeier CC. Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia. Cancer Cell, 2025, 43: 482-502.e9.","journal-title":"Cancer Cell"},{"key":"CITATION175","doi-asserted-by":"publisher","first-page":"100917","DOI":"10.1016\/j.xcrm.2023.100917","volume":"4","author":"Wu L","year":"2023","unstructured":"Wu L, Brzostek J, Sakthi Vale PD, Wei Q, Koh CKT, Ong JXH, Wu L. CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance. Cell Rep Med, 2023, 4: 100917.","journal-title":"Cell Rep Med"},{"key":"CITATION176","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-18-2559","volume":"25","author":"Drent E","year":"2019","unstructured":"Drent E, Poels R, Ruiter R, van de Donk NWCJ, Zweegman S, Yuan H, de Bruijn J. Combined CD28 and 4-1BB costimulation potentiates affinity-tuned chimeric antigen receptor\u2013engineered T cells. Clin Cancer Res, 2019, 25: 4014-4025.","journal-title":"Clin Cancer Res"},{"key":"CITATION177","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","volume":"2","author":"Hirabayashi K","year":"2021","unstructured":"Hirabayashi K, Du H, Xu Y, Shou P, Zhou X, Fuc\u00e1 G, Landoni E. Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat Cancer, 2021, 2: 904-918.","journal-title":"Nat Cancer"},{"key":"CITATION178","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.celrep.2018.03.084","volume":"23","author":"Ecker C","year":"2018","unstructured":"Ecker C, Guo L, Voicu S, Gil-de-G\u00f3mez L, Medvec A, Cortina L, Pajda J. Differential reliance on lipid metabolism as a salvage pathway underlies functional differences of T cell subsets in poor nutrient environments. Cell Rep, 2018, 23: 741-755.","journal-title":"Cell Rep"},{"key":"CITATION179","doi-asserted-by":"publisher","first-page":"113412","DOI":"10.1016\/j.intimp.2024.113412","volume":"143","author":"Li W","year":"2024","unstructured":"Li W, Chen J, Guo Z. Targeting metabolic pathway enhance CAR-T potency for solid tumor. Int Immunopharmacol, 2024, 143: 113412.","journal-title":"Int Immunopharmacol"},{"key":"CITATION180","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12291-023-01166-9","volume":"40","author":"Jalil AT","year":"2025","unstructured":"Jalil AT, Al-Kazzaz HH, Hassan FA, Mohammed SH, Merza MS, Aslandook T, Elewadi A. Metabolic reprogramming of anti-cancer T cells: targeting AMPK and PPAR to optimize cancer immunotherapy. Ind J Clin Biochem, 2025, 40: 165-175.","journal-title":"Ind J Clin Biochem"},{"key":"CITATION181","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cmet.2025.04.008","volume":"37","author":"Niu C","year":"2025","unstructured":"Niu C, Wei H, Pan X, Wang Y, Song H, Li C, Qie J. Foxp3 confers long-term efficacy of chimeric antigen receptor-T cells via metabolic reprogramming. Cell Metab, 2025, 37: 1426-1441.e7.","journal-title":"Cell Metab"},{"key":"CITATION182","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","volume":"629","author":"Chan JD","year":"2024","unstructured":"Chan JD, Scheffler CM, Munoz I, Sek K, Lee JN, Huang YK, Yap KM. FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy. Nature, 2024, 629: 201-210.","journal-title":"Nature"},{"key":"CITATION183","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cell.2016.05.035","volume":"166","author":"Buck MD","year":"2016","unstructured":"Buck MD, O\u2019Sullivan D, Klein Geltink RI, Curtis JD, Chang CH, Sanin DE, Qiu J. Mitochondrial dynamics controls T cell fate through metabolic programming. Cell, 2016, 166: 63-76.","journal-title":"Cell"},{"key":"CITATION184","doi-asserted-by":"publisher","first-page":"e006522","DOI":"10.1136\/jitc-2022-006522","volume":"11","author":"Lontos K","year":"2023","unstructured":"Lontos K, Wang Y, Joshi SK, Frisch AT, Watson MLJ, Kumar A, Menk AV. Metabolic reprogramming via an engineered PGC-1\u03b1 improves human chimeric antigen receptor T-cell therapy against solid tumors. J Immunother Cancer, 2023, 11: e006522.","journal-title":"J Immunother Cancer"},{"key":"CITATION185","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1038\/s41423-020-0365-3","volume":"18","author":"Dumauthioz N","year":"2021","unstructured":"Dumauthioz N, Tschumi B, Wenes M, Marti B, Wang H, Franco F, Li W. Enforced PGC-1\u03b1 expression promotes CD8 T cell fitness, memory formation and antitumor immunity. Cell Mol Immunol, 2021, 18: 1761-1771.","journal-title":"Cell Mol Immunol"},{"key":"CITATION186","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/s41586-018-0282-0","volume":"559","author":"Borges da Silva H","year":"2018","unstructured":"Borges da Silva H, Beura LK, Wang H, Hanse EA, Gore R, Scott MC, Walsh DA. The purinergic receptor P2RX7 directs metabolic fitness of long-lived memory CD8+ T cells. Nature, 2018, 559: 264-268.","journal-title":"Nature"},{"key":"CITATION187","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.3389\/fimmu.2020.01834","volume":"11","author":"Li W","year":"2020","unstructured":"Li W, Zhang L. Rewiring mitochondrial metabolism for CD8+ T cell memory formation and effective cancer immunotherapy. Front Immunol, 2020, 11: 1834.","journal-title":"Front Immunol"},{"key":"CITATION188","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.immuni.2016.08.009","volume":"45","author":"Scharping NE","year":"2016","unstructured":"Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins SC, Ferris RL. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity, 2016, 45: 701-703.","journal-title":"Immunity"},{"key":"CITATION189","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.cmet.2024.12.007","volume":"37","author":"Frisch AT","year":"2025","unstructured":"Frisch AT, Wang Y, Xie B, Yang A, Ford BR, Joshi S, Kedziora KM. Redirecting glucose flux during in vitro expansion generates epigenetically and metabolically superior T cells for cancer immunotherapy. Cell Metab, 2025, 37: 870-885.e8.","journal-title":"Cell Metab"},{"key":"CITATION190","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.immuni.2021.04.008","volume":"54","author":"Xu K","year":"2021","unstructured":"Xu K, Yin N, Peng M, Stamatiades EG, Chhangawala S, Shyu A, Li P. Glycolytic ATP fuels phosphoinositide 3-kinase signaling to support effector T helper 17 cell responses. Immunity, 2021, 54: 976-987.e7.","journal-title":"Immunity"},{"key":"CITATION191","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.celrep.2019.08.068","volume":"29","author":"Renner K","year":"2019","unstructured":"Renner K, Bruss C, Schnell A, Koehl G, Becker HM, Fante M, Menevse AN. Restricting glycolysis preserves T cell effector functions and augments checkpoint therapy. Cell Rep, 2019, 29: 135-150.e9.","journal-title":"Cell Rep"},{"key":"CITATION192","doi-asserted-by":"publisher","first-page":"115153","DOI":"10.1016\/j.bcp.2022.115153","volume":"202","author":"Lei J","year":"2022","unstructured":"Lei J, Yang Y, Lu Z, Pan H, Fang J, Jing B, Chen Y. Taming metabolic competition via glycolysis inhibition for safe and potent tumor immunotherapy. Biochem Pharmacol, 2022, 202: 115153.","journal-title":"Biochem Pharmacol"},{"key":"CITATION193","doi-asserted-by":"publisher","first-page":"e27573","DOI":"10.4161\/onci.27573","volume":"3","author":"Sukumar M","year":"2014","unstructured":"Sukumar M, Gattinoni L. The short and sweet of T-cell therapy. OncoImmunology, 2014, 3: e27573.","journal-title":"OncoImmunology"},{"key":"CITATION194","doi-asserted-by":"publisher","first-page":"669456","DOI":"10.3389\/fimmu.2021.669456","volume":"12","author":"Martins CP","year":"2021","unstructured":"Martins CP, New LA, O\u2019Connor EC, Previte DM, Cargill KR, Tse IL, Sims- Lucas S. Glycolysis inhibition induces functional and metabolic exhaustion of CD4+ T cells in type 1 diabetes. Front Immunol, 2021, 12: 669456.","journal-title":"Front Immunol"},{"key":"CITATION195","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1186\/s13046-019-1409-3","volume":"38","author":"Yin Z","year":"2019","unstructured":"Yin Z, Bai L, Li W, Zeng T, Tian H, Cui J. Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy. J Exp Clin Cancer Res, 2019, 38: 403.","journal-title":"J Exp Clin Cancer Res"},{"key":"CITATION196","doi-asserted-by":"publisher","first-page":"eaaz6314","DOI":"10.1126\/scitranslmed.aaz6314","volume":"13","author":"Liu X","year":"2021","unstructured":"Liu X, Hartman CL, Li L, Albert CJ, Si F, Gao A, Huang L. Reprogramming lipid metabolism prevents effector T cell senescence and enhances tumor immunotherapy. Sci Transl Med, 2021, 13: eaaz6314.","journal-title":"Sci Transl Med"},{"key":"CITATION197","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.tem.2024.11.014","volume":"36","author":"Rumiano L","year":"2025","unstructured":"Rumiano L, Manzo T. Lipids guide T cell antitumor immunity by shaping their metabolic and functional fitness. Trends Endocrinol Metab, 2025, 36: 802-814.","journal-title":"Trends Endocrinol Metab"},{"key":"CITATION198","doi-asserted-by":"publisher","first-page":"e010403","DOI":"10.1136\/jitc-2024-010403","volume":"13","author":"Xu Y","year":"2025","unstructured":"Xu Y, Ding L, Wu M, Wang X, Wang L, Xu Z, Xia Y. Lipid metabolic remodeling delays senescence of T cells to potentiate their immunity against solid tumors. J Immunother Cancer, 2025, 13: e010403.","journal-title":"J Immunother Cancer"},{"key":"CITATION199","doi-asserted-by":"publisher","first-page":"eaaz6667","DOI":"10.1126\/scitranslmed.aaz6667","volume":"12","author":"Hao M","year":"2020","unstructured":"Hao M, Hou S, Li W, Li K, Xue L, Hu Q, Zhu L. Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy. Sci Transl Med, 2020, 12: eaaz6667.","journal-title":"Sci Transl Med"},{"key":"CITATION200","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ccell.2017.08.004","volume":"32","author":"Zhang Y","year":"2017","unstructured":"Zhang Y, Kurupati R, Liu L, Zhou XY, Zhang G, Hudaihed A, Filisio F. Enhancing CD8+ T Cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy. Cancer Cell, 2017, 32: 377-391.e9.","journal-title":"Cancer Cell"},{"key":"CITATION201","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12944-022-01705-y","volume":"21","author":"Lou W","year":"2022","unstructured":"Lou W, Gong C, Ye Z, Hu Y, Zhu M, Fang Z, Xu H. Lipid metabolic features of T cells in the tumor microenvironment. Lipids Health Dis, 2022, 21: 94.","journal-title":"Lipids Health Dis"},{"key":"CITATION202","doi-asserted-by":"publisher","first-page":"189259","DOI":"10.1016\/j.bbcan.2025.189259","volume":"1880","author":"Yang L","year":"2025","unstructured":"Yang L, Wang X, Wang S, Shen J, Li Y, Wan S, Xiao Z. Targeting lipid metabolism in regulatory T cells for enhancing cancer immunotherapy. Biochim Biophys Acta Rev Cancer, 2025, 1880: 189259.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"CITATION203","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40820-020-00555-6","volume":"13","author":"Kim D","year":"2021","unstructured":"Kim D, Wu Y, Li Q, Oh YK. Nanoparticle-mediated lipid metabolic reprogramming of T cells in tumor microenvironments for immunometabolic therapy. Nano-Micro Lett, 2021, 13: 31.","journal-title":"Nano-Micro Lett"},{"key":"CITATION204","doi-asserted-by":"publisher","first-page":"1090429","DOI":"10.3389\/fimmu.2022.1090429","volume":"13","author":"Chen C","year":"2022","unstructured":"Chen C, Wang Z, Ding Y, Qin Y. Manipulating T-cell metabolism to enhance immunotherapy in solid tumor. Front Immunol, 2022, 13: 1090429.","journal-title":"Front Immunol"},{"key":"CITATION205","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.semcdb.2019.05.012","volume":"98","author":"Mat\u00e9s JM","year":"2020","unstructured":"Mat\u00e9s JM, Di Paola FJ, Campos-Sandoval JA, Mazurek S, M\u00e1rquez J. Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer. Semin Cell Dev Biol, 2020, 98: 34-43.","journal-title":"Semin Cell Dev Biol"},{"key":"CITATION206","doi-asserted-by":"publisher","first-page":"114943","DOI":"10.1016\/j.bcp.2022.114943","volume":"198","author":"Sharma S","year":"2022","unstructured":"Sharma S, Agnihotri N, Kumar S. Targeting fuel pocket of cancer cell metabolism: a focus on glutaminolysis. Biochem Pharmacol, 2022, 198: 114943.","journal-title":"Biochem Pharmacol"},{"key":"CITATION207","doi-asserted-by":"publisher","first-page":"1032360","DOI":"10.3389\/fcell.2022.1032360","volume":"10","author":"Valvo V","year":"2022","unstructured":"Valvo V, Parietti E, Deans K, Ahn SW, Park NR, Ferland B, Thompson D. High-throughput in situ perturbation of metabolite levels in the tumor micro-environment reveals favorable metabolic condition for increased fitness of infiltrated T-cells. Front Cell Dev Biol, 2022, 10: 1032360.","journal-title":"Front Cell Dev Biol"},{"key":"CITATION208","doi-asserted-by":"publisher","first-page":"189257","DOI":"10.1016\/j.bbcan.2024.189257","volume":"1880","author":"Dong C","year":"2024","unstructured":"Dong C, Zhao Y, Han Y, Li M, Wang G. Targeting glutamine metabolism crosstalk with tumor immune response. Biochim Biophys Acta Rev Cancer, 2024, 1880: 189257.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"CITATION209","doi-asserted-by":"publisher","first-page":"104876","DOI":"10.1016\/j.phrs.2020.104876","volume":"159","author":"Wang T","year":"2020","unstructured":"Wang T, Shen Y, Luyten S, Yang Y, Jiang X. Tissue-resident memory CD8+ T cells in cancer immunology and immunotherapy. Pharmacol Res, 2020, 159: 104876.","journal-title":"Pharmacol Res"},{"key":"CITATION210","doi-asserted-by":"publisher","first-page":"e20201605","DOI":"10.1084\/jem.20201605","volume":"218","author":"Ok\u0142a K","year":"2021","unstructured":"Ok\u0142a K, Farber DL, Zou W. Tissue-resident memory T cells in tumor immunity and immunotherapy. J Exp Med, 2021, 218: e20201605.","journal-title":"J Exp Med"},{"key":"CITATION211","doi-asserted-by":"crossref","unstructured":"Abadir E, Wayte R, Li W, Gupta S, Yang S, Reaiche E, Debosz K, et al. Reduced CAR T expansion post infusion is associated with poor survival in patients with large B cell lymphoma after two or more therapies. Transplant Cell Ther 2025.","DOI":"10.1016\/j.jtct.2025.01.001"},{"key":"CITATION212","doi-asserted-by":"publisher","first-page":"eabk1900","DOI":"10.1126\/scitranslmed.abk1900","volume":"15","author":"Meyran D","year":"2023","unstructured":"Meyran D, Zhu JJ, Butler J, Tantalo D, MacDonald S, Nguyen TN, Wang M. TSTEM-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models. Sci Transl Med, 2023, 15: eabk1900.","journal-title":"Sci Transl Med"},{"key":"CITATION213","doi-asserted-by":"publisher","first-page":"1064339","DOI":"10.3389\/fimmu.2022.1064339","volume":"13","author":"Ung S","year":"2022","unstructured":"Ung S, Choochuen P, Khopanlert W, Maneechai K, Sangkhathat S, Terakura S, Julamanee J. Enrichment of T-cell proliferation and memory gene signatures of CD79A\/CD40 costimulatory domain potentiates CD19 CAR-T cell functions. Front Immunol, 2022, 13: 1064339.","journal-title":"Front Immunol"},{"key":"CITATION214","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41590-024-02042-1","volume":"26","author":"Song F","year":"2025","unstructured":"Song F, Tsahouridis O, Stucchi S, Walhart T, Mendell S, Hardy PB, Axtman M. A multi-kinase inhibitor screen identifies inhibitors preserving stem-cell-like chimeric antigen receptor T cells. Nat Immunol, 2025, 26: 279-293.","journal-title":"Nat Immunol"},{"key":"CITATION215","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.ccell.2020.05.004","volume":"37","author":"Gurusamy D","year":"2020","unstructured":"Gurusamy D, Henning AN, Yamamoto TN, Yu Z, Zacharakis N, Krishna S, Kishton RJ. Multi-phenotype CRISPR-Cas9 screen identifies p38 kinase as a target for adoptive immunotherapies. Cancer Cell, 2020, 37: 818-833.e9.","journal-title":"Cancer Cell"},{"key":"CITATION216","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41392-024-01986-y","volume":"9","author":"Wang X","year":"2024","unstructured":"Wang X, Tao X, Chen P, Jiang P, Li W, Chang H, Wei C. MEK inhibition prevents CAR-T cell exhaustion and differentiation via downregulation of c-Fos and JunB. Sig Transduct Target Ther, 2024, 9: 293.","journal-title":"Sig Transduct Target Ther"},{"key":"CITATION217","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-024-07300-8","volume":"629","author":"Doan AE","year":"2024","unstructured":"Doan AE, Mueller KP, Chen AY, Rouin GT, Chen Y, Daniel B, Lattin J. FOXO1 is a master regulator of memory programming in CAR T cells. Nature, 2024, 629: 211-218.","journal-title":"Nature"},{"key":"CITATION218","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.immuni.2013.07.013","volume":"39","author":"Kim MV","year":"2013","unstructured":"Kim MV, Ouyang W, Liao W, Zhang MQ, Li MO. The transcription factor foxo1 controls central-memory CD8+ T cell responses to infection. Immunity, 2013, 39: 286-297.","journal-title":"Immunity"},{"key":"CITATION219","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"Lynn RC","year":"2019","unstructured":"Lynn RC, Weber EW, Sotillo E, Gennert D, Xu P, Good Z, Anbunathan H. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature, 2019, 576: 293-300.","journal-title":"Nature"},{"key":"CITATION220","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.imlet.2009.12.019","volume":"128","author":"Guo Z","year":"2010","unstructured":"Guo Z, Wang G, Miyahara Y, Khattar M, Linkes SP, Wang C, Xia J. IL-7, but not thymic stromal lymphopoietin (TSLP), during priming enhances the generation of memory CD4+ T cells. Immunol Lett, 2010, 128: 116-123.","journal-title":"Immunol Lett"},{"key":"CITATION221","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1158\/1078-0432.CCR-23-1872","volume":"30","author":"Nguyen R","year":"2024","unstructured":"Nguyen R, Doubrovina E, Mousset CM, Jin BY, Okada R, Zhang X, Clavel A. Cooperative armoring of CAR and TCR T cells by T cell\u2013restricted IL15 and IL21 universally enhances solid tumor efficacy. Clin Cancer Res, 2024, 30: 1555-1566.","journal-title":"Clin Cancer Res"},{"key":"CITATION222","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.immuni.2018.08.002","volume":"49","author":"Snell LM","year":"2018","unstructured":"Snell LM, MacLeod BL, Law JC, Osokine I, Elsaesser HJ, Hezaveh K, Dickson RJ. CD8+ T cell priming in established chronic viral infection preferentially directs differentiation of memory-like cells for sustained immunity. Immunity, 2018, 49: 678-694.e5.","journal-title":"Immunity"},{"key":"CITATION223","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","volume":"637","author":"Steffin D","year":"2025","unstructured":"Steffin D, Ghatwai N, Montalbano A, Rathi P, Courtney AN, Arnett AB, Fleurence J. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature, 2025, 637: 940-946.","journal-title":"Nature"},{"key":"CITATION224","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","volume":"42","author":"Zhao Y","year":"2024","unstructured":"Zhao Y, Chen J, Andreatta M, Feng B, Xie YQ, Wenes M, Wang Y. IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nat Biotechnol, 2024, 42: 1693-1704.","journal-title":"Nat Biotechnol"},{"key":"CITATION225","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41586-024-07962-4","volume":"634","author":"Feng B","year":"2024","unstructured":"Feng B, Bai Z, Zhou X, Zhao Y, Xie YQ, Huang X, Liu Y. The type 2 cytokine Fc\u2013IL-4 revitalizes exhausted CD8+ T cells against cancer. Nature, 2024, 634: 712-720.","journal-title":"Nature"},{"key":"CITATION226","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/btm2.10097","volume":"3","author":"Hou AJ","year":"2018","unstructured":"Hou AJ, Chang ZNL, Lorenzini MH, Zah E, Chen YY. TGF-\u03b2\u2013responsive CAR-T cells promote anti-tumor immune function. Bioeng Transla Med, 2018, 3: 75-86.","journal-title":"Bioeng Transla Med"},{"key":"CITATION227","doi-asserted-by":"publisher","first-page":"e3002943","DOI":"10.1371\/journal.pbio.3002943","volume":"22","author":"Lawton ML","year":"2024","unstructured":"Lawton ML, Inge MM, Blum BC, Smith-Mahoney EL, Bolzan D, Lin W, McConney C. Multiomic profiling of chronically activated CD4+ T cells identifies drivers of exhaustion and metabolic reprogramming. PLoS Biol, 2024, 22: e3002943.","journal-title":"PLoS Biol"},{"key":"CITATION228","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","volume":"37","author":"McLane LM","year":"2019","unstructured":"McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol, 2019, 37: 457-495.","journal-title":"Annu Rev Immunol"},{"key":"CITATION229","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.immuni.2024.11.026","volume":"58","author":"Waibl Polania J","year":"2025","unstructured":"Waibl Polania J, Hoyt-Miggelbrink A, Tomaszewski WH, Wachsmuth LP, Lorrey SJ, Wilkinson DS, Lerner E. Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion. Immunity, 2025, 58: 232-246.e6.","journal-title":"Immunity"},{"key":"CITATION230","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ccell.2025.01.013","volume":"43","author":"Porazzi P","year":"2025","unstructured":"Porazzi P, Nason S, Yang Z, Carturan A, Ghilardi G, Guruprasad P, Patel RP. EZH1\/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. Cancer Cell, 2025, 43: 537-551.e7.","journal-title":"Cancer Cell"},{"key":"CITATION231","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.ymthe.2019.02.014","volume":"27","author":"Kailayangiri S","year":"2019","unstructured":"Kailayangiri S, Altvater B, Lesch S, Balbach S, G\u00f6ttlich C, K\u00fchnemundt J, Mikesch JH. EZH2 inhibition in ewing sarcoma upregulates GD2 expression for targeting with gene-modified T cells. Mol Ther, 2019, 27: 933-946.","journal-title":"Mol Ther"},{"key":"CITATION232","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ccell.2024.11.006","volume":"43","author":"Isshiki Y","year":"2025","unstructured":"Isshiki Y, Chen X, Teater M, Karagiannidis I, Nam H, Cai W, Meydan C. EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function. Cancer Cell, 2025, 43: 49-68.e9.","journal-title":"Cancer Cell"},{"key":"CITATION233","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"Fraietta JA","year":"2018","unstructured":"Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, Cogdill AP. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature, 2018, 558: 307-312.","journal-title":"Nature"},{"key":"CITATION234","doi-asserted-by":"publisher","first-page":"eadp9371","DOI":"10.1126\/sciadv.adp9371","volume":"10","author":"Dimitri AJ","year":"2024","unstructured":"Dimitri AJ, Baxter AE, Chen GM, Hopkins CR, Rouin GT, Huang H, Kong W. TET2 regulates early and late transitions in exhausted CD8+ T cell differentiation and limits CAR T cell function. Sci Adv, 2024, 10: eadp9371.","journal-title":"Sci Adv"},{"key":"CITATION235","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40164-025-00609-8","volume":"14","author":"Kim Y","year":"2025","unstructured":"Kim Y, Jeun M, Lee HK, Choi JU, Park S, Park CH. TET2 downregulation enhances the antitumor efficacy of CD19 CAR T cells in a preclinical model. Exp Hematol Oncol, 2025, 14: 23.","journal-title":"Exp Hematol Oncol"},{"key":"CITATION236","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41586-022-05692-z","volume":"615","author":"Jain N","year":"2023","unstructured":"Jain N, Zhao Z, Feucht J, Koche R, Iyer A, Dobrin A, Mansilla-Soto J. TET2 guards against unchecked BATF3-induced CAR T cell expansion. Nature, 2023, 615: 315-322.","journal-title":"Nature"},{"key":"CITATION237","doi-asserted-by":"publisher","first-page":"114065","DOI":"10.1016\/j.celrep.2024.114065","volume":"43","author":"Zhu M","year":"2024","unstructured":"Zhu M, Han Y, Gu T, Wang R, Si X, Kong D, Zhao P. Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway. Cell Rep, 2024, 43: 114065.","journal-title":"Cell Rep"},{"key":"CITATION238","doi-asserted-by":"publisher","first-page":"e2317694121","DOI":"10.1073\/pnas.2317694121","volume":"121","author":"McGuire CK","year":"2024","unstructured":"McGuire CK, Meehan AS, Couser E, Bull L, Minor AC, Kuhlmann-Hogan A, Kaech SM. Transcriptional repression by HDAC3 mediates T cell exclusion from Kras mutant lung tumors. Proc Natl Acad Sci USA, 2024, 121: e2317694121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"CITATION239","doi-asserted-by":"publisher","first-page":"1533044","DOI":"10.3389\/fimmu.2025.1533044","volume":"16","author":"Jo DH","year":"2025","unstructured":"Jo DH, Kaczmarek S, Khan AUH, Pervin J, Clark DM, Gadde S, Wang L. Entinostat, a histone deacetylase inhibitor, enhances CAR-NK cell anti-tumor activity by sustaining CAR expression. Front Immunol, 2025, 16: 1533044.","journal-title":"Front Immunol"},{"key":"CITATION240","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41392-022-00915-1","volume":"7","author":"Yan X","year":"2022","unstructured":"Yan X, Chen D, Wang Y, Guo Y, Tong C, Wei J, Zhang Y. Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies. Sig Transduct Target Ther, 2022, 7: 98.","journal-title":"Sig Transduct Target Ther"},{"key":"CITATION241","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1158\/2326-6066.CIR-14-0159","volume":"3","author":"Berrien-Elliott MM","year":"2015","unstructured":"Berrien-Elliott MM, Yuan J, Swier LE, Jackson SR, Chen CL, Donlin MJ, Teague RM. Checkpoint blockade immunotherapy relies on T-bet but not eomes to induce effector function in tumor-infiltrating CD8+ T cells. Cancer Immunol Res, 2015, 3: 116-124.","journal-title":"Cancer Immunol Res"},{"key":"CITATION242","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","volume":"571","author":"Khan O","year":"2019","unstructured":"Khan O, Giles JR, McDonald S, Manne S, Ngiow SF, Patel KP, Werner MT. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature, 2019, 571: 211-218.","journal-title":"Nature"},{"key":"CITATION243","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","volume":"571","author":"Scott AC","year":"2019","unstructured":"Scott AC, D\u00fcndar F, Zumbo P, Chandran SS, Klebanoff CA, Shakiba M, Trivedi P. TOX is a critical regulator of tumour-specific T cell differentiation. Nature, 2019, 571: 270-274.","journal-title":"Nature"},{"key":"CITATION244","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-019-1326-9","volume":"571","author":"Alfei F","year":"2019","unstructured":"Alfei F, Kanev K, Hofmann M, Wu M, Ghoneim HE, Roelli P, Utzschneider DT. TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature, 2019, 571: 265-269.","journal-title":"Nature"},{"key":"CITATION245","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.immuni.2015.01.006","volume":"42","author":"Martinez GJ","year":"2015","unstructured":"Martinez GJ, Pereira RM, \u00c4ij\u00f6 T, Kim EY, Marangoni F, Pipkin ME, Togher S. The transcription factor NFAT promotes exhaustion of activated CD8+\u2005T cells. Immunity, 2015, 42: 265-278.","journal-title":"Immunity"},{"key":"CITATION246","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.immuni.2015.01.023","volume":"42","author":"Bengsch B","year":"2015","unstructured":"Bengsch B, Wherry EJ. The importance of cooperation: partnerless NFAT induces T cell exhaustion. Immunity, 2015, 42: 203-205.","journal-title":"Immunity"},{"key":"CITATION247","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/cdd.2014.19","volume":"21","author":"Grusdat M","year":"2014","unstructured":"Grusdat M, McIlwain DR, Xu HC, Pozdeev VI, Knievel J, Crome SQ, Robert-Tissot C. IRF4 and BATF are critical for CD8+ T-cell function following infection with LCMV. Cell Death Differ, 2014, 21: 1050-1060.","journal-title":"Cell Death Differ"},{"key":"CITATION248","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.immuni.2017.11.021","volume":"47","author":"Man K","year":"2017","unstructured":"Man K, Gabriel SS, Liao Y, Gloury R, Preston S, Henstridge DC, Pellegrini M. Transcription factor IRF4 promotes CD8+ T cell exhaustion and limits the development of memory-like T cells during chronic infection. Immunity, 2017, 47: 1129-1141.e5.","journal-title":"Immunity"},{"key":"CITATION249","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41590-021-00964-8","volume":"22","author":"Seo H","year":"2021","unstructured":"Seo H, Gonz\u00e1lez-Avalos E, Zhang W, Ramchandani P, Yang C, Lio CWJ, Rao A. BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. Nat Immunol, 2021, 22: 983-995.","journal-title":"Nat Immunol"},{"key":"CITATION250","doi-asserted-by":"publisher","first-page":"e008665","DOI":"10.1136\/jitc-2023-008665","volume":"12","author":"Nakagawara K","year":"2024","unstructured":"Nakagawara K, Ando M, Srirat T, Mise-Omata S, Hayakawa T, Ito M, Fukunaga K. NR4A ablation improves mitochondrial fitness for long persistence in human CAR-T cells against solid tumors. J Immunother Cancer, 2024, 12: e008665.","journal-title":"J Immunother Cancer"},{"key":"CITATION251","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","volume":"567","author":"Chen J","year":"2019","unstructured":"Chen J, L\u00f3pez-Moyado IF, Seo H, Lio CWJ, Hempleman LJ, Sekiya T, Yoshimura A. NR4A transcription factors limit CAR T cell function in solid tumours. Nature, 2019, 567: 530-534.","journal-title":"Nature"},{"key":"CITATION252","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.apsb.2019.09.006","volume":"10","author":"Chen X","year":"2020","unstructured":"Chen X, Pan X, Zhang W, Guo H, Cheng S, He Q, Yang B. Epigenetic strategies synergize with PD-L1\/PD-1 targeted cancer immunotherapies to enhance antitumor responses. Acta Pharm Sin B, 2020, 10: 723-733.","journal-title":"Acta Pharm Sin B"},{"key":"CITATION253","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.scib.2024.11.029","volume":"70","author":"Zhou X","year":"2025","unstructured":"Zhou X, Zhou F, Zhang L. Dual inhibition of PD-1 and LAG-3: Uncovering mechanisms to reverse T cell exhaustion and enhance anti-tumor immunity. Sci Bull, 2025, 70: 624-626.","journal-title":"Sci Bull"},{"key":"CITATION254","doi-asserted-by":"publisher","first-page":"e001749","DOI":"10.1136\/jitc-2020-001749","volume":"9","author":"Van Damme H","year":"2021","unstructured":"Van Damme H, Dombrecht B, Kiss M, Roose H, Allen E, Van Overmeire E, Kancheva D. Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy. J Immunother Cancer, 2021, 9: e001749.","journal-title":"J Immunother Cancer"},{"key":"CITATION255","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12943-023-01731-z","volume":"22","author":"Pei L","year":"2023","unstructured":"Pei L, Liu Y, Liu L, Gao S, Gao X, Feng Y, Sun Z. Roles of cancer-associated fibroblasts (CAFs) in anti-PD-1\/PD-L1 immunotherapy for solid cancers. Mol Cancer, 2023, 22: 29.","journal-title":"Mol Cancer"},{"key":"CITATION256","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-023-01725-x","volume":"22","author":"Zhang H","year":"2023","unstructured":"Zhang H, Liu L, Liu J, Dang P, Hu S, Yuan W, Sun Z. Roles of tumor-associated macrophages in anti-PD-1\/PD-L1 immunotherapy for solid cancers. Mol Cancer, 2023, 22: 58.","journal-title":"Mol Cancer"},{"key":"CITATION257","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2326-6066.CIR-21-0515","volume":"10","author":"Budimir N","year":"2022","unstructured":"Budimir N, Thomas GD, Dolina JS, Salek-Ardakani S. Reversing T-cell exhaustion in cancer: lessons learned from PD-1\/PD-L1 immune checkpoint blockade. Cancer Immunol Res, 2022, 10: 146-153.","journal-title":"Cancer Immunol Res"},{"key":"CITATION258","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"Grosser R","year":"2019","unstructured":"Grosser R, Cherkassky L, Chintala N, Adusumilli PS. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell, 2019, 36: 471-482.","journal-title":"Cancer Cell"},{"key":"CITATION259","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3390\/ijms19020340","volume":"19","author":"Yoon D","year":"2018","unstructured":"Yoon D, Osborn M, Tolar J, Kim C. Incorporation of immune checkpoint blockade into chimeric antigen receptor T cells (CAR-Ts): combination or built-in CAR-T. Int J Mol Sci, 2018, 19: 340.","journal-title":"Int J Mol Sci"},{"key":"CITATION260","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jcyt.2023.03.011","volume":"25","author":"Lau E","year":"2023","unstructured":"Lau E, Kwong G, Fowler TW, Sun BC, Donohoue PD, Davis RT, Bryan M. Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness. Cytotherapy, 2023, 25: 750-762.","journal-title":"Cytotherapy"},{"key":"CITATION261","doi-asserted-by":"publisher","first-page":"e1273302","DOI":"10.1080\/2162402X.2016.1273302","volume":"6","author":"Chen N","year":"2017","unstructured":"Chen N, Morello A, Tano Z, Adusumilli PS. CAR T-cell intrinsic PD-1 checkpoint blockade: a two-in-one approach for solid tumor immunotherapy. OncoImmunology, 2017, 6: e1273302.","journal-title":"OncoImmunology"},{"key":"CITATION262","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"Cherkassky L","year":"2016","unstructured":"Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest, 2016, 126: 3130-3144.","journal-title":"J Clin Invest"},{"key":"CITATION263","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"Miller BC","year":"2019","unstructured":"Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, Yates KB. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol, 2019, 20: 326-336.","journal-title":"Nat Immunol"},{"key":"CITATION264","doi-asserted-by":"publisher","first-page":"117252","DOI":"10.1016\/j.biopha.2024.117252","volume":"178","author":"Lin H","year":"2024","unstructured":"Lin H, Yang X, Ye S, Huang L, Mu W. Antigen escape in CAR-T cell therapy: mechanisms and overcoming strategies. Biomed Pharmacother, 2024, 178: 117252.","journal-title":"Biomed Pharmacother"},{"key":"CITATION265","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1016\/j.ymthe.2023.03.020","volume":"31","author":"Kokalaki E","year":"2023","unstructured":"Kokalaki E, Ma B, Ferrari M, Grothier T, Hazelton W, Manzoor S, Costu E. Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR. Mol Ther, 2023, 31: 2089-2104.","journal-title":"Mol Ther"},{"key":"CITATION266","doi-asserted-by":"publisher","first-page":"e82786","DOI":"10.7554\/eLife.82786","volume":"12","author":"George JT","year":"2023","unstructured":"George JT, Levine H. Optimal cancer evasion in a dynamic immune microenvironment generates diverse post-escape tumor antigenicity profiles. eLife, 2023, 12: e82786.","journal-title":"eLife"},{"key":"CITATION267","doi-asserted-by":"publisher","first-page":"e010249","DOI":"10.1136\/jitc-2024-010249","volume":"12","author":"Roerden M","year":"2024","unstructured":"Roerden M, Castro AB, Cui Y, Harake N, Kim B, Dye J, Maiorino L. Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression. J Immunother Cancer, 2024, 12: e010249.","journal-title":"J Immunother Cancer"},{"key":"CITATION268","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41392-022-00898-z","volume":"7","author":"Dai Z","year":"2022","unstructured":"Dai Z, Mu W, Zhao Y, Cheng J, Lin H, Ouyang K, Jia X. T cells expressing CD5\/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape. Sig Transduct Target Ther, 2022, 7: 85.","journal-title":"Sig Transduct Target Ther"},{"key":"CITATION269","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/14712598.2020.1819978","volume":"21","author":"Date V","year":"2021","unstructured":"Date V, Nair S. Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors. Expert Opin Biol Ther, 2021, 21: 145-160.","journal-title":"Expert Opin Biol Ther"},{"key":"CITATION270","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1186\/s12964-024-01995-y","volume":"22","author":"Abdalsalam NMF","year":"2024","unstructured":"Abdalsalam NMF, Ibrahim A, Saliu MA, Liu TM, Wan X, Yan D. MDSC: a new potential breakthrough in CAR-T therapy for solid tumors. Cell Commun Signal, 2024, 22: 612.","journal-title":"Cell Commun Signal"},{"key":"CITATION271","doi-asserted-by":"publisher","first-page":"1493346","DOI":"10.3389\/fphar.2025.1493346","volume":"16","author":"He W","year":"2025","unstructured":"He W, Cui K, Farooq MA, Huang N, Zhu S, Jiang D, Zhang X. TCR-T cell therapy for solid tumors: challenges and emerging solutions. Front Pharmacol, 2025, 16: 1493346.","journal-title":"Front Pharmacol"},{"key":"CITATION272","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13045-021-01115-0","volume":"14","author":"Tsimberidou AM","year":"2021","unstructured":"Tsimberidou AM, Van Morris K, Vo HH, Eck S, Lin YF, Rivas JM, Andersson BS. T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors. J Hematol Oncol, 2021, 14: 102.","journal-title":"J Hematol Oncol"},{"key":"CITATION273","doi-asserted-by":"publisher","first-page":"113617","DOI":"10.1016\/j.jim.2024.113617","volume":"526","author":"Manske K","year":"2024","unstructured":"Manske K, Dre\u00dfler L, Fr\u00e4\u00dfle SP, Effenberger M, Tschulik C, Cletiu V, Benke E. Miniaturized CAR knocked onto CD3\u03b5 extends TCR function with CAR specificity under control of endogenous TCR signaling cascade. J Immunol Methods, 2024, 526: 113617.","journal-title":"J Immunol Methods"},{"key":"CITATION274","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.isatra.2023.06.001","volume":"140","author":"Li C","year":"2023","unstructured":"Li C, Zhao X, Wu C, Liu L, Zhao N. Periodic event-triggered dynamic output feedback control for networked control systems subject to packet dropouts. ISA Trans, 2023, 140: 97-108.","journal-title":"ISA Trans"},{"key":"CITATION275","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/s41565-021-00982-5","volume":"16","author":"Nguyen NT","year":"2021","unstructured":"Nguyen NT, Huang K, Zeng H, Jing J, Wang R, Fang S, Chen J. Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety. Nat Nanotechnol, 2021, 16: 1424-1434.","journal-title":"Nat Nanotechnol"},{"key":"CITATION276","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1016\/j.cell.2025.02.035","volume":"188","author":"Liu L","year":"2025","unstructured":"Liu L, He P, Wang Y, Ma F, Li D, Bai Z, Qu Y. Engineering sonogenetic EchoBack-CAR T cells. Cell, 2025, 188: 2621-2636.e20.","journal-title":"Cell"},{"key":"CITATION277","doi-asserted-by":"publisher","first-page":"eabd8836","DOI":"10.1126\/scitranslmed.abd8836","volume":"13","author":"Hyrenius-Wittsten A","year":"2021","unstructured":"Hyrenius-Wittsten A, Su Y, Park M, Garcia JM, Alavi J, Perry N, Montgomery G. SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Sci Transl Med, 2021, 13: eabd8836.","journal-title":"Sci Transl Med"},{"key":"CITATION278","doi-asserted-by":"publisher","first-page":"eabe7378","DOI":"10.1126\/scitranslmed.abe7378","volume":"13","author":"Choe JH","year":"2021","unstructured":"Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA, Downey KM. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med, 2021, 13: eabe7378.","journal-title":"Sci Transl Med"},{"key":"CITATION279","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.3389\/fonc.2019.01448","volume":"9","author":"Luo H","year":"2019","unstructured":"Luo H, Wu X, Sun R, Su J, Wang Y, Dong Y, Shi B. Target-dependent expression of IL12 by synNotch receptor-engineered NK92 cells increases the antitumor activities of CAR-T cells. Front Oncol, 2019, 9: 1448.","journal-title":"Front Oncol"},{"key":"CITATION280","doi-asserted-by":"publisher","first-page":"1489827","DOI":"10.3389\/fimmu.2024.1489827","volume":"15","author":"Khan SH","year":"2024","unstructured":"Khan SH, Choi Y, Veena M, Lee JK, Shin DS. Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors. Front Immunol, 2024, 15: 1489827.","journal-title":"Front Immunol"},{"key":"CITATION281","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1038\/s41467-020-15729-4","volume":"11","author":"Wang Z","year":"2020","unstructured":"Wang Z, Wang F, Zhong J, Zhu T, Zheng Y, Zhao T, Xie Q. Using apelin-based synthetic Notch receptors to detect angiogenesis and treat solid tumors. Nat Commun, 2020, 11: 2163.","journal-title":"Nat Commun"},{"key":"CITATION282","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1158\/2326-6066.CIR-18-0551","volume":"7","author":"Smith EL","year":"2019","unstructured":"Smith EL, Mailankody S, Staehr M, Wang X, Senechal B, Purdon TJ, Daniyan AF. BCMA-targeted CAR T-cell therapy plus radiotherapy for the treatment of refractory myeloma reveals potential synergy. Cancer Immunol Res, 2019, 7: 1047-1053.","journal-title":"Cancer Immunol Res"},{"key":"CITATION283","doi-asserted-by":"publisher","first-page":"648655","DOI":"10.3389\/fonc.2021.648655","volume":"11","author":"Fang PQ","year":"2021","unstructured":"Fang PQ, Gunther JR, Wu SY, Dabaja BS, Nastoupil LJ, Ahmed S, Neelapu SS. Radiation and CAR T-cell therapy in lymphoma: future frontiers and potential opportunities for synergy. Front Oncol, 2021, 11: 648655.","journal-title":"Front Oncol"},{"key":"CITATION284","doi-asserted-by":"publisher","first-page":"108763","DOI":"10.1016\/j.pharmthera.2024.108763","volume":"266","author":"Misawa K","year":"2025","unstructured":"Misawa K, Bhat H, Adusumilli PS, Hou Z. Combinational CAR T-cell therapy for solid tumors: requisites, rationales, and trials. Pharmacol Ther, 2025, 266: 108763.","journal-title":"Pharmacol Ther"},{"key":"CITATION285","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40259-024-00669-y","volume":"38","author":"Holtermann A","year":"2024","unstructured":"Holtermann A, Gislon M, Angele M, Subklewe M, von Bergwelt-Baildon M, Lauber K, Kobold S. Prospects of synergy: local interventions and CAR T cell therapy in solid tumors. BioDrugs, 2024, 38: 611-637.","journal-title":"BioDrugs"},{"key":"CITATION286","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1080\/17460441.2021.1929920","volume":"16","author":"Hull CM","year":"2021","unstructured":"Hull CM, Maher J. Approaches for refining and furthering the development of CAR-based T cell therapies for solid malignancies. Expert Opin Drug Discov, 2021, 16: 1105-1117.","journal-title":"Expert Opin Drug Discov"},{"key":"CITATION287","doi-asserted-by":"publisher","first-page":"1777064","DOI":"10.1080\/2162402X.2020.1777064","volume":"9","author":"Alcantara M","year":"2020","unstructured":"Alcantara M, Du Rusquec P, Romano E. Current clinical evidence and potential solutions to increase benefit of CAR T-cell therapy for patients with solid tumors. OncoImmunology, 2020, 9: 1777064.","journal-title":"OncoImmunology"},{"key":"CITATION288","doi-asserted-by":"publisher","first-page":"1037934","DOI":"10.3389\/fonc.2022.1037934","volume":"12","author":"Liu Y","year":"2022","unstructured":"Liu Y, Zheng Y, Deng T, Huang Y, Liu Z, Zhan B, Zhou X. Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy. Front Oncol, 2022, 12: 1037934.","journal-title":"Front Oncol"},{"key":"CITATION289","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.7150\/thno.84946","volume":"13","author":"Sun S","year":"2023","unstructured":"Sun S, Ding Z, Gao L, Hammock BD, Huang X, Xu ZP, Wang X. A dendritic\/tumor fusion cell vaccine enhances efficacy of nanobody-based CAR-T cells against solid tumor. Theranostics, 2023, 13: 5099-5113.","journal-title":"Theranostics"},{"key":"CITATION290","doi-asserted-by":"publisher","first-page":"e2100157","DOI":"10.1002\/adhm.202100157","volume":"10","author":"Su FY","year":"2021","unstructured":"Su FY, Mac QD, Sivakumar A, Kwong GA. Interfacing biomaterials with synthetic T cell immunity. Adv Healthcare Mater, 2021, 10: e2100157.","journal-title":"Adv Healthcare Mater"},{"key":"CITATION291","doi-asserted-by":"publisher","first-page":"122580","DOI":"10.1016\/j.biomaterials.2024.122580","volume":"308","author":"Pandit S","year":"2024","unstructured":"Pandit S, Agarwalla P, Song F, Jansson A, Dotti G, Brudno Y. Implantable CAR T cell factories enhance solid tumor treatment. Biomaterials, 2024, 308: 122580.","journal-title":"Biomaterials"},{"key":"CITATION292","unstructured":"Huang M, Deng J, Gao L, Zhou J. Innovative strategies to advance CAR T cell therapy for solid tumors.  Am J Cancer Res  2020, 10: 1979\u20131992."},{"key":"CITATION293","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1080\/14712598.2018.1473368","volume":"18","author":"Shum T","year":"2018","unstructured":"Shum T, Kruse RL, Rooney CM. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities. Expert Opin Biol Ther, 2018, 18: 653-664.","journal-title":"Expert Opin Biol Ther"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.sciengine.com\/doi\/pdf\/DF89FC8BFEB544CE838A45FDD59E923B","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2025190","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/pdf\/DF89FC8BFEB544CE838A45FDD59E923B","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T08:34:20Z","timestamp":1769675660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2025190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":293,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10,23]]},"published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.3724\/abbs.2025190","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,23]]}}}